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Asthma is a chronic respiratory disease characterized by reversible airway
obstruction, persistent airway hyperresponsiveness, chronic airway inflammation, and
chronic airway remodeling. Most adult asthmatics have neutrophilic airway inflammation
that correlates to increasing disease severity, and fail to respond to corticosteroid
therapies that mitigate other asthma endotypes. Accordingly, there is a need to investigate
the molecular mechanisms responsible for neutrophilic asthma. Pasture heaves, a
respiratory disease affecting horses housed on pasture in conditions of high heat and
humidity, shares the aforementioned characteristics of human asthma, including
neutrophilic inflammation. The cause is undetermined, but genetic propensities for
reactivity to seasonally inhaled, pasture-associated, aeroallergens are presumed.
Complexities of diseases like asthma and pasture heaves, that include temporal
interactions between environmental and genetic factors, lend themselves to exploration
using -omics technologies.
An emergent paradigm in disease pathogenesis views disease as the result
of imbalances in a biological system of thousands of proteins that maintain eukaryotic

homeostasis. Consistent with this paradigm, this dissertation describes systematic efforts
to identify groups of proteins in the bronchoalveolar lavage fluids of horses with pasture
heaves that are altered in a manner that influences neutrophilic airway inflammation, and
are similarly changed in human asthma. This is the first use of -omics technologies to
investigate pasture heaves. This was accomplished first by improving functional
annotation of the equine genome by providing functional annotation for an equine
oligoarray, thereby facilitating future functional modeling of equine gene products. Next,
through comparative modeling of protein functions in normal bronchoalveolar lavage
fluid (BALF) proteomes from horse, human, and mouse, we demonstrated conservation
of protein functions in lung fluids across these species. Finally, comparative modeling of
pasture heaves-affected and non-diseased BALF proteomes demonstrated that proteins in
diseased BALF favor airway neutrophilic inflammation by increasing neutrophil
migration, chemotaxis, adhesion, detachment, transmigration, and degranulation, while
reducing activation, cell spreading, infiltration, phagocytosis, respiratory burst, apoptosis,
and clearance. Collectively, these molecular events contribute to airway neutrophilic
inflammation in pasture heaves, and are conserved in human asthma. This method further
validates pasture heaves as a robust model for human neutrophilic asthma, and highlights
proteins of potential clinical and therapeutic relevance.
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CHAPTER I
INTRODUCTION

Asthma is a genetically heterogenous, chronic lung disease that affects adults and
children of all ages, and can present in a variety of clinical forms. It is caused by a
combination of complex and incompletely understood environmental and genetic
interactions [1]. Accounts of asthmatic symptoms have been in medical literature from
the time of Hippocrates [2], and by the late 19th century, physicians accepted asthma as a
distinct disease with a specific set of causes, clinical changes, and treatment [3]. Over
time, understanding and monitoring of asthma has improved. In the 1980s, the CDC
began conducting National Health Interview Surveys monitoring the prevalence of
asthma, which has been increasing since the start of surveillance [4]. Currently, the CDC
estimates that 8% of American adults and 9.3% of American children have asthma, 18.7
million and 6.8 million people, respectively [5].
The four characteristics that define asthma are: chronic inflammation, persistent
airway hyperresponsiveness (AHR), reversible airway obstruction, and airway
remodeling. Environmental and other factors (such as inhaled aeroallergens, irritants, and
viruses) provoke airway inflammation in asthmatics [6]. There is an underlying chronic
inflammation present in asthmatic patients that occurs even in the absence of continued
allergen exposure [7]. Many inflammatory cells play a role in the inflammation of
asthma, including mast cells, neutrophils, eosinophils, T-lymphocytes, macrophages,
1

neutrophils, and epithelial cells [8]. Traditionally, airway inflammation in asthma was
thought to be predominantly eosinophilic, but more recent literature indicates that greater
than 50% of adult asthmatics have a neutrophilic inflammation, correlating to increasing
severity of disease [9-11].
Airway hyperresponsiveness (AHR) describes a condition of increased airway
narrowing in response to a bronchoconstrictive challenge [12].Originally thought to be
due solely to inflammation, two components to airway hyperresponsiveness are now
recognized: persistent and variable AHR. Variable AHR, named for the fact that this type
of AHR is variably present, is believed to relate to the inflammatory events of the airway,
which vary depending on stimulus. By contrast, persistent AHR refers to AHR that
remains even after removal of the inciting agent/allergen/antigen for protracted periods.
Persistent AHR is associated with structural changes in the airway [13].
The asthma diagnosis hinges upon documentation that airway narrowing during
an asthmatic episode is reversible, either spontaneously or through treatment. Airflow
obstruction is caused by a variety of changes in the airway, including
bronchoconstriction, edema, mucus plug formation, and airway remodeling. Although
the airway obstruction is reversible, the histopathological lesions of asthma, collectively
termed "airway remodeling," are not fully reversible [14, 15]. Remodeling changes
contribute to a thickening of airway epithelium and airway smooth muscle with
subsequent reduction of airway diameter. These changes result in fixed airflow
obstruction with asthma progression. Remodeling also results in compromised epithelial
barrier function, mucus gland hypersecretion, goblet cell hyperplasia and metaplasia, and
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airway fibrosis [16-21]. Significantly, airway remodeling is known to correlate to the
clinical severity of asthma [22-24].
Many animal species have been used as models of asthma, which are crucial to
the continual development of new therapeutic mechanisms and furthering understanding
of disease. The complex nature of asthma makes it difficult to find an animal model that
possesses all key facets of asthma, including reversible airway obstruction, persistent
airway hyperresponsiveness, chronic inflammation, and airway remodeling; while
remaining cost-effective, easy to use, and with findings that translate directly to humans.
The rat, guinea pig, and mouse are the classic, laboratory animal models. They are
relatively inexpensive and convenient to keep, but in these models, disease is not
naturally occurring and must be induced. Rodents have significant limitations as asthma
models because, with continued antigen stimulation, they develop tolerance to antigen
sensitization protocols used to induce disease, and airway hyperresponsiveness does not
persist when antigen sensitization protocols are discontinued [25]. Larger asthma models
have been induced in the dog, sheep, swine, cattle, and monkey, whose greater size
facilitates lung function testing. However, like rodents, these models are not naturally
occurring. Only the horse and cat develop a spontaneous asthma-like syndrome that
demonstrates a high level of similarity to the human condition [15]. The most interesting
difference between the two is that cats have a predominantly eosinophilic inflammation
[26-28], while horses possess a neutrophilic inflammation [29-31].
Recurrent airway obstruction (RAO), also known as ‘equine heaves’ or ‘chronic
obstructive pulmonary disease (COPD),' is an asthma-like disease of horses, and is one of
the most commonly diagnosed conditions affecting the equine lung [32]. RAO is a
3

spontaneous, naturally-occurring progressive allergic respiratory disorder characterized
by periods of acute airway obstruction, followed by periods of remission [33]. Two forms
of the disease have been described: traditional RAO, or "barn-associated RAO," which
occurs more commonly in temperate climates [34]; and "pasture heaves," or "summer
pasture-associated recurrent airway obstruction" (SPARAO), which affects horses on
pasture during the summer in hot and humid climates such as the southeastern United
States and Great Britain [35, 36]. The incidence of RAO is rare in warm and dry climates
[34]. In barn-associated RAO, disease typically occurs during the winter months, in
stabled horses exposed to organic molds found in hay [37], while in pasture heaves
disease is associated with horses housed primarily on pasture during spring and summer
months. The direct cause of pasture heaves is unknown, but inhalation of pollens or
molds are thought to be the main contributors [38]. Clinical exacerbation has also been
correlated with increases in temperature, humidity, fungal spore counts, and grass pollens
[39].
During disease exacerbation, horses suffer respiratory distress episodes similar to
severe human asthmatics, displaying wheezing, coughing, and labored breathing as an
airway response to inhaled aeroallergens [40]. During periods of disease remission,
RAO-affected horses appear clinically normal, with airway function and cytology similar
to nonaffected horses [41]. Significantly, their airways remain hyperresponsive to stimuli,
and remodeling is persistent [42]; findings that are consistent in humans with neutrophilic
asthma [43].
Like human asthma, RAO and pasture heaves are spontaneous diseases that occur
in an outbred population, in response to an environmental aeroallergen challenge. RAO
4

and pasture heaves possesses all four of the key facets of human asthma: chronic airway
inflammation, persistent airway hyperresponsiveness, reversible airway obstruction, and
airway remodeling [31, 39, 44-46]. Additionally, the airway inflammation associated
with RAO and pasture heaves is predominantly neutrophilic, similar to severely affected
human asthmatics. Combined, these facets of RAO and pasture heaves make the diseases
an excellent model for human asthma, particularly the neutrophilic phenotype. Based
upon these clinical similarities, we hypothesize that horses with pasture heaves share
protein networks that are relevant to asthmatic AHR and neutrophilic inflammation.
Accordingly, the objective of this research is to employ genome-scale expression data to
identify molecular signatures of asthmatic airway hyperresponsiveness and neutrophilic
airway inflammation in pasture heaves horses.
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CHAPTER II
LITERATURE REVIEW

Asthma overview
History and prevalence of asthma
Asthma is a chronic respiratory disorder characterized by variable and recurring
episodes of impaired breathing, cough, and wheezing. Exacerbations reflect airflow
obstruction, bronchial hyperresponsiveness, and airway inflammation [1]. Incidences of
asthma have been noted throughout most of recorded human history. In fact, the word
"asthma" in Greek, means "to exhale with open mouth, to pant," and the first time the
word appeared was in The Iliad, a Homer Greek epic poem. In 460-360 BC, Hippocrates
was the first to use it as a medical term, or sign, and the first description of asthma as a
disease was in the first century AD, by Aretaeus of Cappadocia [2]. It was not until the
late 19th century when physicians accepted asthma as its own distinct disease [3]. As the
world became modernized, asthma prevalence began to increase, partially due to
increasing acceptance of the disease, improving medical care, and increases in
environmental aeroallergens that came along with human advancements. Effective
monitoring of asthma really began in the 1980s, through the CDC's National Health
Interview Surveys. Today, asthma prevalence continues to increase, now affecting more
than 300 million people worldwide, including an estimated 8% of American adults and
9.3% of American children [4]. In addition to being a prevalent disease, asthma is costly.
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In 2007, the CDC estimated the cost of asthma $56 billion dollars per year in medical
costs and lost revenue[5].
Causes of asthma
Asthma is a multifactorial disease, resulting from a complex, incompletely
understood interaction between genes and environmental exposure [6, 7]. Traditionally,
asthma was considered an atopic disease, reflecting an inherited predisposition to IgE
production in which exposure to allergens causes IgE mediated clinical signs of disease
[8]. To date, atopy remains 'the strongest identifiable predisposing factor for developing
asthma’ with viral respiratory infections being ‘one of the most important causes of
asthma exacerbation’ which ‘may also contribute to the development of asthma’ [1].
Allergens that have been associated with this form of asthma include fungus, mold,
animal dander, cockroach, house dust mite, and pollen [9-12]. However, the propensity to
produce IgE in response to allergen challenge (atopy) affects approximately half of the
adult population, and most atopic patients fail to develop asthma [8].
Within the last two decades, researchers have implicated many other factors in the
development of asthma, including environmental factors such as air pollution, including
ozone, particulate matter, and nitrogen dioxide, weather, and irritants [11, 13-16], and
lifestyle decisions that include stress, diet, exercise patterns, obesity, tobacco smoke, and
infection [17-20]. Greater than 100 genes have been identified that are likely to contribute
to the different manifestations of asthma [21]. A limited number of genes have been
associated with severe asthma, and before the advancements of genome-wide association
studies (GWAS), only a few genes were implicated in development of severe asthma;
most significantly, polymorphisms within interleukin 4-receptor alpha (IL4RA) [22],
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which binds IL13 and IL4, increasing IgE levels [23, 24]. In two adult steroid-refractory
asthma cohorts, amino acid substitutions in the intracellular signaling portion of IL4RA,
within the minor alleles at E375A and Q551R, were associated with severe exacerbations
and reduced lung function [25]. Another study concluded that the IL4-589T allele is a
risk factor for near fatal, life-threatening asthma attacks [26].
Since 2007, there have been extensive studies to identify susceptible candidate
genes based on genome-wide association studies (GWAS), but for severe asthma, results
remain unclear [27]. In 2007, Chupp et al. conducted a GWAS of asthmatics stratified by
severity of disease, and concluded that YKL-40 and its encoding gene CHI3L1 may be
new biomarkers for severity of asthma [28]. YKL-40 is a chitinase-like protein that is
involved in inflammation and remodeling [29]. Ober et al. performed a GWAS in 2008,
confirming that CHI3L1 was a susceptibility gene for asthma, airway
hyperresponsiveness, and reduced lung function, and that elevated YKL-40 levels were
biomarkers for asthma and decreased lung function [29]. In 2010, two GWAS that
included patients with severe, refractory asthma revealed Th2-like genes of importance
on chromosome 5q, including RAD50, IL13, and TSLP [30, 31]. The protein encoded by
RAD50 is involved in DNA double-strand break repair and has no known function
directly related to asthma [30], TSLP has been shown to induce the production of Th2attracting chemokines, such as TARC and CCL17, and prime Th2 T cell development
[32], and the involvement of IL13 in many aspects of allergic asthma, including
inflammation and remodeling been investigated for decades [24, 33]. Association with
HLA-DQB1, a human leukocyte antigen that has been shown to be involved in antigenic
presentation [34], was also noted in the 2010 GWAS conducted by Li et al. [30].
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Hawkins et al. (2012) identified the IL6R coding SNP rs2228145 (Asp358Ala) as a
potential genetic modifier of lung function in asthma, and as a novel genetic marker of
asthma severity [35]. IL6R has been correlated with increased levels of inflammation
through cytokine signalling dysregulation resulting in the activation of janus kinase 2
(JAK2) and STAT3 [35, 36]. GWAS have also identified the 17q12-21 locus encoding
ORMDL3 which regulates the regulating metalloproteases, chemokines, OAS, and ATF6
[37], and GSDMB which regulates apoptosis, as predominantly associated with
childhood-onset asthma [38]. Significantly, a GWAS performed by Moffatt et al. (2010)
showed increased ORMDL3 expression only in childhood-onset asthma, and not in adultonset asthma, or severe asthma, and that elevation of serum IgE levels only had a minor
role in development of asthma [31]. Continued efforts to elucidate the genetic
underpinnings of asthma are extensive and the diversity of these findings is consistent
with the emerging concept of differences in asthma pathophysiology directing grouping
by endotypes.
Signs, symptoms, and diagnosis of asthma
Impaired breathing during asthma exacerbations is largely reflective of asthma’s
three cardinal components: reversible airway obstruction (bronchoconstriction), airway
inflammation, and airway hyperresponsiveness (AHR) to aeroallergens [39, 40].
Symptoms include shortness of breath and chest tightness, as well as clinically evident
wheezing. Airway inflammation and mucus accumulation contributes to coughing.
Asthma severity ranges from mild, with occasional disease exacerbation, to more severe
disease that adversely affects the patient's quality of life.
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Asthma diagnosis hinges on documentation of 1) airway obstruction that is
reversible, typically in response to ß2-adrenoceptor agonists; 2) AHR to non-specific
spasmogens (eg methacholine or hypertonic saline); 3) chronic airway inflammation; and
4) a medical history consistent with shortness of breath, chest tightness, cough, recurrent
wheezing, nocturnal worsening of disease, and symptom triggers [41-43]. Advancing
disease is associated with histologic changes in small and large airways that are
collectively termed airway remodeling and are diagnosed using endobronchial biopsy
[44]. Airway remodeling in asthma includes subepithelial fibrosis, increased airway
smooth muscle mass, goblet and mucus gland hyperplasia, angiogenesis, loss of cartilage
integrity, inflammation, and epithelial alterations. As asthma severity increases, the
severity of airway obstruction, AHR, inflammation, and remodeling also progress [45].
Salient features of asthma
Reversible airway obstruction
The clinical manifestations of asthma including shortness of breath, wheezing,
and coughing, are directly caused by airway obstruction [46]. Airflow obstruction results
from a variety of changes that collectively contribute to airway narrowing, including
bronchoconstriction, airway edema, mucus hypersecretion, and airway remodeling [47].
Airway remodeling refers to a set of histologic changes that include airway obstruction,
goblet cell hyperplasia and metaplasia, mucus hypersecretion, thickening of airway
epithelium, airway fibrosis, and smooth muscle proliferation [44, 48-52]. The precise
contribution of these factors varies between asthmatic patients, resulting in diverse
clinical expression, disease severity, and varying therapeutic responses [46].
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The asthma diagnosis hinges upon documentation of airway obstruction that is
reversible. Two cell types are predominantly responsible for the changes that lead to
airway obstruction: airway epithelial cells and airway smooth muscle cells [53]. When an
asthmatic patient inhales, environmental stimuli that include aeroallergens, viruses, and
pollutants perturb airway epithelial cells, stimulating neurologic pathways that result in
acetylcholine mediated constriction of airway smooth muscle [53, 54]. Concurrently,
these stimuli also act on airway epithelial cells that produce inflammatory mediators and
contribute to goblet cell metaplasia, mucus secretion, and airway smooth muscle
contraction [54-56]. Goblet cells within the epithelium secrete mucus and epithelial cells
produce inflammatory mediators, including cytokines and interleukins [54-56]. The
resultant overproduction of mucus ultimately leads to the formation of mucus plugs,
which account for significant mechanical obstruction of the airways [46]. In addition,
inflammatory mediators increase capillary membrane permeability that promotes
interstitial edema [46] and direct the infiltration of inflammatory cells [48], further
contributing to airway narrowing. Inflammatory cascades also cause surrounding airway
smooth muscle to become more contractile [46]. However, airway inflammation alone is
not enough to explain neither the severity nor the progression of asthma [57, 58]. In fact,
repeated bronchoconstriction without additional inflammation has been shown to be
sufficient to induce airway remodeling, opening the door to investigations of the role of
airway smooth muscle as a major mediator of asthmatic bronchoconstriction as well as
inflammation [59, 60].
Airway smooth muscle (ASM) is a pivotal cell type in the overall pathogenesis of
asthma [61]. ASM is the major cell type responsible for bronchoconstriction and in
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addition, mediates airway inflammation, airway hyperresponsiveness, and chronic lung
function impairment [61, 62]. These latter effects are discussed in more detail in the
following sections. Airway smooth muscle is increased in both large and small airways in
asthmatic patients [63-65], and correlates to asthma severity [63, 66]. Asthmatic ASM
also has a greater velocity of contraction [67, 68], but even in the absence of changes in
contractile properties, increased muscle mass is a major factor in asthmatic airway
obstruction [69]. In addition to acetylcholine-mediated smooth muscle contraction, the
diversity of inflammatory mediators released in asthma have both direct and indirect
effects on augmenting airway smooth muscle contraction [46].
Airway hyperresponsiveness
Airway hyperresponsiveness (AHR) describes a condition of exaggerated airway
narrowing in response to a bronchoconstrictive challenge, and it is a universal and
defining feature of asthma [70, 71]. There is wide variability of intensity of AHR
between patients, and even within the same patient, but intensity often correlates to
severity of disease [72]. AHR is complex in its mechanisms; originally thought to be due
solely to inflammation. Two semi-independent components of airway
hyperresponsiveness are now recognized: persistent and variable AHR [62, 73].
Variable AHR is acute, transient, and reversible, and is believed to relate to the
inflammatory events of the airway, which vary depending on stimulus [72, 74]. The
variable component of AHR is associated with current allergen exposure, asthma activity,
and disease severity [75]. Although the link to airway inflammation is strong, the precise
mechanisms between airway inflammation and AHR are not entirely clear. By contrast,
persistent AHR refers to AHR that remains even after removal of the inciting
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agent/allergen/antigen for protracted periods. Persistent AHR is related to chronicity of
disease and to the structural changes in the airway that define airway remodeling,
including subepithelial thickening, smooth muscle hypertrophy, and extracellular matrix
deposition [72, 74]. Some patients with mild or episodic asthma may only exhibit
variable AHR and not persistent AHR [75].
Measurement of AHR is influenced by the methods used to detect it, which are
divided into direct or indirect stimulation. Direct stimulation of the airway,
predominantly used to study persistent AHR, is usually performed using methacholine or
histamine, which act directly on airway smooth muscle (ASM), causing a contractile
response that narrows the airways [72, 76]. A variety of indirect activators are used to
detect variable AHR, including aerosolized hypertonic saline and mannitol, and
adenosine monophosphate, which acts on mast cells to release mediators [74]. Histamine
also elicits indirect stimulation, as it activates sensory fibers in the airway, leading to a
reflex response that amplifies bronchospasm [74].
During much of the previous three decades, the dominant opinion was that asthma
was a predominantly inflammatory disease. This opinion was formed based on the
conclusions of studies that noted a relationship between AHR, inflammation, and
remodeling [77]. However, that theory has been challenged by studies reporting a lack of
a relationship between lung function, inflammation, and morphology [78, 79]. One such
study, by Kariyawasam et al. (2007), evaluated the effects of allergic inflammation on
AHR 24 hours and 7 days after an antigen challenge. After 24 hours there was AHR
present in response to a methacholine as well as an increase in eosinophilia, but at 7 days,
when the eosinophils were back at baseline levels, procollagen cells, a marker for airway
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remodeling, were present [80]. This suggested that the structural changes of the airway
are greater contributors than inflammation to AHR, and that eosinophils are not causative
of AHR [80]. New computational models have shown that AHR is the result of complex
interactions among ASM, remodeling, inflammation, load, and breathing patterns, but
many functional features have been ascribed to ASM [69, 81, 82].
Airway inflammation
In asthmatics, airway inflammation can be caused by exposure to environmental
and other factors (such as inhaled aeroallergens, irritants, and viruses) [83], but there is
an underlying chronic inflammation present that occurs even in the absence of continued
allergen exposure and obvious asthmatic symptoms [84, 85]. Many inflammatory cells
play a role in the inflammation of asthma, including mast cells, neutrophils, eosinophils,
T-lymphocytes, macrophages, neutrophils, and epithelial cells [86]. The eosinophil was
long considered the effecter cell of airway inflammation, but more recent literature
indicates that greater than 50% of adult asthmatics have a predominantly neutrophilic
inflammation, correlating to increasing severity of disease [87-89].
Eosinophils are still believed to play an important role in the airway inflammation
present in allergic asthma patients, through the release of inflammatory mediators such as
leukotrienes, cytokines, and radical oxygen species [90, 91]. There is debate within the
literature to the extent of involvement of the eosinophil in the causation of airway
hyperresponsiveness, but studies have shown that when asthma patients with a persistent
eosinophilia are treated with anti IL-5 mAb, which reduces eosinophil numbers, their
quality of life improves, with reduced exacerbations and a reduction in the amount and
frequency of their need for systemic corticosteroids [92]. However, some studies
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demonstrate that even after this treatment, there is still no reduction in airway
hyperresponsiveness, suggesting that eosinophils may not be a prerequisite for airway
hyperresponsiveness [58]. Steroid resistance has been described as lack of improvement
of lung function and demonstration of airway hyperresponsiveness despite treatment with
corticosteroids [93, 94]. Although eosinophilic asthma is generally responsive to
corticosteroids, there is evidence that some patients continue to have persistent
eosinophilia, thickened subepithelial basement membranes, and higher incidences of
asthma-related morbidity despite treatment [95-97]. Contrary to asthmatics with
eosinophilic airway inflammation, most cases of steroid resistant asthma are patients with
neutrophilic airway inflammation [98, 99].
Most cases of severe asthma have a predominant airway neutrophilia, with
numbers that correlate to an increased disease severity [87-89]. Interleukins (IL) -8 and 17, both of which are upregulated in severe asthmatics, have been shown to play an
important role in the accumulation of neutrophils at sites of inflammation [100-103].
Neutrophils have been recognized as the major inflammatory cell present in acute severe
asthma that requires mechanical ventilation [101]. Further, in fatal asthma attacks,
bronchiolar neutrophilic inflammation predominates and eosinophilic inflammation is
less prevalent. This finding has led to the hypothesis that fatal attacks of asthma may be
triggered by stimuli that elicit neutrophilic inflammatory responses [104].
It is now known that airway smooth muscle is a pivotal cell type mediating airway
inflammation. Through the upregulation of cell adhesion molecules including
intracellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and CD44,
ASM interacts with inflammatory cells including T-cells, mast cells, eosinophils, and
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neutrophils [105]. ASM produces numerous cytokines such as IL-1ß, IL-5, IL-6, IL-8,
and IL-17. IL-6 is produced when ASM is stimulated by other cytokines, including IL-1ß
or TNF-α, and IL-6 can induce ASM hyperplasia [106]. ASM also has other autocrine
effects, one example being the presentation of bacterial superantigen toCD4+ T cells to
enhance production of IL-13, a proinflammatory cytokine, which can in turn evoke
changes in ASM constriction [107]. ASM also produces chemokines that recruit and
retain inflammatory cells, including eotaxin, MCP-1, MCP-2, MCP-3, RANTES,
CXCL8, CXCL10, fractalkine, and thymus-regulated and activation-regulated
chemokine. [108-114]. In addition to typical inflammatory factors, growth factors such as
VEGF, BDNF, and TGF-ß can be secreted by ASM cells [115, 116]. Airway smooth
muscle responsiveness to and ability to excrete an array of inflammatory mediators is an
important part of the inflammatory response in asthma, and the modulation of
inflammatory responses by ASM may be a potential therapeutic target.
Histopathology of asthma: airway remodeling
Histopathologic changes in asthmatic lung collectively referred to as airway
remodeling were first described in 1922 in fatal cases of asthma, and since then have
been documented in all degrees of asthma severity [117]. Airway remodeling refers to the
structural histopathological changes that occur in asthmatic airways over time [118].
Unlike airway obstruction, remodeling changes are incompletely reversible [119, 120],
and can result in fixed (non-reversible) airflow obstruction as asthma progresses [121].
The most significant remodeling changes contribute to increased airway smooth muscle
and thickening of the airway epithelium, but other changes include compromised
epithelial barrier function, mucus gland hypersecretion, goblet cell hyperplasia and
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metaplasia, and airway fibrosis [44, 48-52]. Significantly, airway remodeling is known to
correlate to the clinical severity of asthma [122-124].
Airway smooth muscle thickening
Airway smooth muscle is present in both the large and small airways of both
healthy patients and asthmatics [125]. Increased airway smooth muscle (ASM) mass is
the most prominent feature of airway remodeling [63], and is thought to be the result of a
combination of hyperplasia, hypertrophy, migration of airway smooth muscle cells
towards the epithelium, and a decreased rate of apoptosis [66, 126, 127], although ASM
hyperplasia seems to be more dominant and significant than hypertrophy [125]. James et
al. (2012) proposed that different forms of remodeling of ASM may account for
differences in the severity of asthma, with increased hyperplasia correlating to disease
severity [117].
Increased hyperplasia of airway smooth muscle cells in asthmatics can be
explained in part by the stimulus of mitogens, chemical compounds that initiate cell
division and mitosis. There are many mitogens, including TGF-ß, IL-1, IL-6,
leukotrienes, histamine, serotonin, and others [128]. These mediators function as ASM
mitogens, increasing ASM mass by binding to receptor tyrosine kinases, G proteincoupled receptors, and cytokine receptors [129].
Airway epithelial thickening
Increased airway wall thickening has consistently been associated with increased
asthma severity [130-132]. Airway wall changes result from a combination of epithelial
cell alterations, subepithelial thickening, submucosal gland hyperplasia, and increased
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airway smooth muscle mass [48, 65, 133, 134]. Epithelial cell alterations include
shedding of the epithelium, goblet cell hyperplasia and metaplasia, and upregulation of
cytokines and growth factors [135]. Thickening of the subepithelial layer is characterized
by increased deposition of extracellular matrix proteins such as collagens, proteoglycans,
and glycoproteins [136, 137], which are produced by fibroblasts and myofibroblasts.
These changes occur in the lamina reticularis, and the thickened reticular layer is largely
composed of collagen I, III, V, and fibronectin [134].
Epithelial barrier function
The airway epithelium is the interface between the inhaled environment and
internal tissues, and its normal function is to form a physical barrier against inhaled
particles such as allergens or pathogens [118, 138, 139]. This physical barrier has two
primary components, the mucociliary clearance apparatus [140], and epithelial tight
junctions [141].
The epithelium of the airways is covered by surface liquid that is composed of a
periciliary layer around microvilli, and an overlying mucus layer where inhaled particles
are trapped [142]. The mucins that comprise the mucus layer are produced throughout the
bronchial tree, by goblet cells, and mucus and serous cells of the submucosal glands
[143]. Mucociliary clearance involves the movement of mucus-trapped inhaled particles
from the airways towards the oropharynx, by the coordinated beating of the cilia [144]. In
the normal lung, ciliated columnar, goblet cells, and Clara cells form a highly regulated
and impermeable barrier, made possible through the formation of tight junctions [142].
Tight junctions enable communications between adjacent cells and regulate intercellular
transport [145, 146]. Further maintenance of the epithelial integrity is through adherens
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junctions, desmosomes, and hemidesmosomes [147]. Disruption of this barrier, the first
line of defense in the lung, enables penetration of the airway wall by pathogens and
particles [148, 149].
In patients with asthma, there is evidence that the barrier function of the airway
epithelium is impaired [146], with loss of columnar cells and enhanced expression of
epidermal growth factor receptor in areas of damage [150, 151]. Disruption of tight
junctions and loss of junctional proteins has also been recorded in asthmatic patients
[152]. Asthmatic patients have increased mucus secretion from goblet cells that are
metaplastic and hyperplastic [153], as well as overall increased amounts of mucins in
sputum compared to levels in normal induced sputum [154], both which contribute to
mucociliary clearance dysfunction, and result in airway obstruction [147].
Repair responses occur after airway epithelial damage, but are often incomplete or
abnormal. Incomplete repair can lead to a scenario not unlike a chronic wound [139],
where secondary growth factors are secreted, driving structural changes linked to airway
remodeling. This includes abnormal subepithelial collagen deposition, which may
contribute to an alternative protective barrier in the absence of a functional epithelium
[147].
Goblet cell hyperplasia/metaplasia, mucus gland hypersecretion
Goblet cells produce and secrete mucin glycoproteins (MUC) into the airway
lumen, which in turn trap foreign particles leading to removal via the mucociliary
escalator. Thirteen mucin proteins have been identified in human airways [129], and the
predominant mucin is MUC5AC, which is increased in asthmatic patients relative to
healthy patients [155]. Mucin production must be tightly regulated, as overproduction can
23

impair proper mucociliary clearance, and eventually contribute to airway obstruction
[149].
Goblet cell hyperplasia has been consistently demonstrated in mild, moderate, and
severe cases of asthma, correlating with increasing disease severity [119, 156] and is
widely acknowledged as a key component of airway remodeling in asthma [50, 119, 123,
124]. One study demonstrated that in mild asthma the hyperplastic goblet cells increase
mucin storage while in moderate asthma the mucin is overstored and secreted, concluding
that altered secretion of mucin may be related to asthma severity [119]. IL-9 and IL-33,
two cytokines that have been implicated in many aspects of asthma pathogenesis, may
play a role in triggering goblet cell hyperplasia and the induction of mucus
hypersecretion [157, 158]. IL-9 has also been implicated in promoting allergic
inflammation, mast cell growth and survival, airway remodeling, and airway
hyperresponsiveness in asthmatic patients [159-161]. Levels of IL-33, an alarmin
cytokine, increase with asthma severity [162], and the gene encoding IL-33 has been
identified as a major susceptibility loci for asthma in GWAS [31, 163-165]. In addition to
its role in goblet cell hyperplasia, IL-33 has been implicated in airway remodeling, Th2type cell differentiation, promoting allergic inflammation and asthma pathogenesis [162,
166].
There are some inconsistencies throughout the literature with regards to the use of
metaplasia and hyperplasia, but hyperplasia refers to proliferation of the same cell type,
while metaplasia refers to cellular differentiation to an alternate cell type. Often,
metaplasia is referred to as hyperplasia. The overall consequences of these abnormalities
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are increased mucus production, airway narrowing due to mucus plugs, and increased
airway wall thickness [63].
Airway fibrosis
Subepithelial collagen deposition is a primary histopathologic alteration observed
in asthmatic lungs [122], and airway fibrosis has been reported in all severities of asthma
[51, 167]. There are conflicting views within the literature in regards to the correlation
between the presence of collagen deposition and asthma severity. Many studies have
associated subepithelial fibrosis with measurements of asthma severity, frequency,
duration of symptoms, and the degree of airway hyperresponsiveness [51, 52, 122, 123,
168-171]. However, other studies have not shown a correlation [124, 172]. Additionally,
some severe asthmatics do not have airway fibrosis [122], and some nonasthmatics do
[173]. However, measurements of limited airway distensibility correlate well with the
magnitude of subepithelial fibrosis [174].
Airway fibrosis plays a role in the pathophysiology of incompletely reversible
airway obstruction that occurs in some asthmatics [175]. Although this process was
initially described as basement membrane thickening, it is now apparent that the true
basement membrane is not grossly altered [134]; instead, the lamina reticularis, which is
just above the basement membrane, is thickened by interstitial collagens [117]. In normal
lungs, this collagen layer is approximately 5mm thick, but in some asthmatic lungs, it has
been reported to increase to 7-23mm [176]. There are inconsistent results with respect to
enhanced collagen deposition in the submucosa, which is between the subepithelium and
smooth muscle [169, 172]. Abnormalities have also been noted in elastin, proteoglycans,
and cartilage [177].
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Treatment of asthma
The most important and efficacious component of asthma therapy is antigen
avoidance. While certain individuals, particularly those with seasonal allergies and
asthma may be helped by allergen immunotherapy, overall there is no conclusive benefit
for this therapy in individuals with year round asthma [178]. In addition, asthma
exacerbations are well known to follow viral respiratory infections, leading to value in
measures that mitigate viral spread and infection, including respiratory viral vaccination
[179, 180].
In humans, asthma is treated primarily with inhaled short and long acting ß2adrenoceptor agonists, which inhibit airway narrowing and closure; and inhaled and oral
preparation of corticosteroids which target the inflammatory components of disease. ß2adrenoceptor agonists are effective bronchodilators due to their ability to antagonize
airway smooth muscle contraction [181]. ß2-receptor activation is mediated by increased
cAMP levels. ß2-adrenoceptor agonists bind to ß2-adrenergic receptors to activate a Gprotein coupled receptor pathway via adenylyl cyclase type 9 (ADCY9). The ADCY9
gene contains a common coding variant, ILe772Met, which alters adenylyl cyclase
activation in response to ß2-adrenoceptor agonists, regulating airway smooth muscle
relaxation [182].
Corticosteroids suppress inflammation in asthma through the activation of many
anti-inflammatory genes, and repression of proinflammatory genes. Corticosteroids
diffuse across cell membranes, binding to glucocorticoid receptors in the cytoplasm [183,
184]. Once bound, the glucocorticoid receptor changes conformation, is released, and
crosses into the nucleus [185], where it homodimerizes, binding to glucocorticoid
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response elements in the promoter region of steroid-responsive genes [186]. This binding
initiates gene transcription through interaction with transcriptional coactivator molecules
such as cyclic AMP response element binding protein-binding protein (CREB). CREB
has histone acetyltransferase activity, which causes the acetylation of core histones,
initiating chromatin remodeling, and recruitment of RNA polymerase II, resulting in gene
activation [187, 188]. Genes that are activated by corticosteroids include antiinflammatory proteins such as glucocorticoid-induced leucine zipper, mitogen-activated
protein kinase phosphatase 1 (MPK-1), lipocortin-1, secretory leukocyte inhibitory
protein, IL-10, IL-12, and IL-1 receptor antagonist [186, 189, 190]. Corticosteroids also
inhibit many inflammatory molecules, including inflammatory cytokines such as IL-2,
IL-3, IL-4, IL-5, IL-6, IL-13, IL-15, TNF-α, GM-CSF, and TSLP; chemokines such as
CCL1, CCL5, CCL11, and CXCL8; inducible nitric oxide synthase; inducible
cylcooxygenase; inducible phospholipase A2; endothelin-1; neurokinin; intracellular cell
adhesion molecule-1; and vascular cell adhesion molecule-1 [190, 191]. This occurs in
two main processes: 1) through glucocorticoid receptors interacting with repressor
molecules to reduce histone acetylation , chromatin remodeling, and RNA polymerase II
actions of proinflammatory transcription factors [192], and 2) through recruitment of
histone deacetylase 2 which deacetylizes the glucocorticoid receptor, allowing
suppression of activated inflammatory genes within the nucleus [186].
After an asthma diagnosis is made, treatment is initiated in steps correlating to
severity of disease and relief of asthma signs and symptoms. These steps are
recommended by the Global Initiative for Asthma:1) an as-needed inhaled short-acting
beta-2 adrenoceptor agonist (SABA), 2) regular low dose inhaled corticosteroid and an
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as-needed SABA, 3) adults- maintenance dose of a combination low dose inhaled
corticosteroid/long acting beta-2 adrenoceptor agonist (LABA) and an as-needed SABA
or combination low dose inhaled corticosteroid/formoterol as maintenance and rescue;
children - moderate dose inhaled corticosteroid plus as needed SABA, 4) adults combination low dose inhaled corticosteroid/formoterol as maintenance and rescue, or
combination medium dose inhaled corticosteroid/LABA and an as-needed SABA;
children- referral to specialist, 5) referral to specialist [193]. When signs and symptoms
have been ameliorated for 2-3 months, titration to the lowest maintenance treatment is
recommended [193].
While an exhaustive review of asthma therapeutics is not relevant to the focus of
this dissertation, second-line asthma therapies include anticholinergic bronchodilators
such as atropine and glycopyrrolate, which can be administered parenterally and
nebulized, and ipratroprium which is nebulized. The methylxanthine bronchodilator,
theophylline, is now infrequently administered to asthmatics due to the heightened risk of
cardiac arrhythmias at increased doses [194].
Adjunctive therapies for control of refractory asthma include the leukotriene
receptor antagonists, montelukast and zafirlukast [195, 196], and the 5-lipoxygenase
inhibitor, zileutonsuch, that inhibits leukotriene synthesis [197]. Leukotriene inhibitors
are potent anti-inflammatory agents that also limit airway smooth muscle constriction by
interfering with the actions of LTA4, LTC4, LTD4, and LTE4 [198-203]. Mast cell
stabilizers of the cromone class (cromolyn) are limited to cromolyn in the United States,
which is administered by nebulization. This agent agents block calcium channels
essential for mast cell degranulation, stabilizing the cell and thereby preventing the
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release of histamine [204, 205]. Omalizumab is a humanized anti-IgE monoclonal
antibody used in patients with elevated IgE levels and allergies to a known allergen
[206]. Omalizumab works to reduce asthma exacerbations, but has a relatively small
effect on airflow [207]. These adjunctive therapeutic agents allow for a reduction in
amount of corticosteroids and ß2-adrenoceptor agonists given to patients, but they are
highly specific, and only affect a small subset of patients.
Therapeutic controversies in asthma
Inhaled ß2-adrenoceptor agonists are among the oldest and most commonly
prescribed treatments for asthma, and they can be divided into three classes: short-acting
ß2-adrenoceptor agonists (SABA), long-acting ß2-adrenoceptor agonists (LABA), and
ultra-long ß2-adrenoceptor agonists [208]. SABAs, such as albuterol, isoproterenol,
terbutaline, and fenoterol, provide rapid symptom relief with bronchodilation, but their
short duration of action makes them inadequate for extended relief. LABAs, such as
formoterol and salmeterol, are designed to alleviate symptoms for longer durations, but
ultra-long ß2-adrenoceptor agonists, including indacaterol and vilanterol, aim to maintain
efficacy while improving dosing convenience with a longer duration than LABAs [209].
For decades, debates have occurred regarding the safety of ß2-adrenoceptor
agonists in asthma therapy. In the 1960s and 1970s, asthma mortality epidemics were
associated with two SABAs, fenoterol and high-dose isoproterenol, but these epidemics
subsided after the SABAs were withdrawn from the market [210, 211]. In 1993, Taylor
et al. discovered that chronic use of inhaled fenoterol increased asthma exacerbations,
airway hyperresponsiveness, and decreased lung function in asthmatic patients, indicating
that chronic administration of short acting ß2-adrenoceptor agonists treatment was
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deleterious to long term asthma control [212]. Also in the early 1990s, the United States
Food and Drug Administration (FDA) requested a surveillance trial to evaluate the safety
of LABAs in 60,000 subjects; this was called the Salmeterol Asthma Multicenter
Research Trial (SMART) [213]. The SMART study was terminated early when analysis
revealed an increase in life-threatening asthma exacerbations and death in subjects taking
LABA compared to placebo [213]. This resulted in a black box warning for all inhaled
LABAs regarding the risk of severe and life-threatening asthma exacerbations [214].
Changes to labels included the contraindication of LABAs without the concomitant use
of inhaled corticosteroids and recommendations that LABAs be used only when
necessary to achieve and maintain control [214, 215]. There is an ongoing FDAmandated international LABA safety study, with expected results in 2017 [214]. This
study is designed to assess the safety of a regimen of LABAs plus inhaled corticosteroids
as compared to corticosteroids alone [214, 216]. Studies have revealed that with LABA
therapy in conjunction with inhaled corticosteroids does not result in increased risk of
death, but in a beneficial effect on asthma control and risk of exacerbation, suggesting
that adverse reactions occur in a small population [217-219].
Other side effects have been documented with frequent or repetitive use of ß2adrenoceptor agonists. Frequent use of ß2-adrenoceptor agonists increases airway
hyperresponsiveness to allergen [220, 221], causes tolerance to the protective effect on
bronchoconstriction [220] and decreases asthma control [222]. More recent evidence
indicates that repetitive use of either short-acting or long-acting ß2-adrenoceptor agonists
leads to reduced bronchoprotection and sensitization of excitation-contraction signalling
pathways in airway smooth muscle cells [223].
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When inhaled corticosteroids were introduced to asthma management, large
improvements were observed in symptom control, lung function, number of
exacerbations, and mortality [224]. Most asthmatic patients are well controlled with low
doses of inhaled corticosteroids [225], but 5-10% of severe asthmatics are refractory to
corticosteroids. Investigations determined that treatment failure corresponded to the
presence of neutrophilic airway inflammation in these patients, with or without
eosinophils, increased tissue injury and remodeling, and are part of the noneosinophilic
asthma endotype [226]. Although this is a small population of people, the increased
disease severity associated with corticosteroid refractory asthma accounts for
approximately half of the total cost of healthcare, and the majority of asthma-related
deaths [227]. Adverse effects associated with corticosteroid use, include immune
suppression, cataracts [228], growth deceleration [229], skin thinning and bruising [230],
osteoporosis[231], and dysphonia [190], although most patients do not experience them,
as they tend to be a result of improper use, inhaler technique, or high doses [193, 232].
Since the introduction of ß2-adrenoceptor agonists and corticosteroids as asthma
therapeutics, few novel therapeutic agents have effectively been translated to clinical use
from animal investigations [233]. Many drugs have done well in animal trials, only to fail
in human testing stages. For example, animal models provided evidence that interleukin13 (IL-13) was necessary to induce all features of allergic asthma, regardless of the other
Th2 cytokines. IL-13 was shown to be upregulated in asthmatics[234], and was supported
in animal models of mice [235], cynomolgus monkeys [236], and sheep [237].
Significant research and funding was invested in biotherapeutics that target IL-13 and its
pathways, but clinical trials have been disappointing [238, 239]. Difficulties in the
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clinical translation of drugs from the traditional mouse model to the human condition are
not unique to asthma. The FDA has acknowledged the limitations of current animal
models across many therapeutic areas, including asthma, and that there is a need for new
models and approaches for further drug development [240].
Asthma endotypes
Traditionally, asthma classification schemes have been based on subjective
parameters and objective assessments that reflected whether disease signs were
intermittent, mild persistent, moderate persistent, or severe persistent [241]. These cases
were all thought to be similar, only differing in their degree of severity, and were
accordingly treated with the same medications, while employing different doses,
frequencies, or routes of administration [242]. For decades, clinicians have recognized
different asthma phenotypes, classifying them based on observable characteristics
including clinical signs, physiologic and morphologic changes, biochemical
characteristics, and response to treatment [241]. These facets remained without formal
characterization. In 2006, it was proposed that asthma be recognized not as a single
disease, but as a complex and heterogeneous syndrome composed of a disease variants,
each with their own pathophysiologies [21]. This has yielded an effort towards
classifying asthma by distinct functional or pathophysiological mechanism, or
‘endotypes’, rather than by overtly observable characteristics. With this method of
classification based upon pathophysiology, it is possible for an endotype to be present in
more than one phenotype, consistent with the natural spectrum that characterizes disease.
Accordingly, the umbrella term "asthma" may be eventually replaced by terms that more
32

accurately describe the actual pathophysiology of diseases that manifest as with signs of
asthma [243].
Currently, the asthma syndrome is divided into several distinct asthma endotypes,
including, but not limited to: allergic asthma, aspirin-sensitive asthma, severe late-onset
hypereosinophilic asthma, allergic bronchopulmonary mycosis, viral-exacerbated asthma,
premenstrual asthma, API-positive preschool wheezer, airflow obstruction caused by
obesity, severe steroid dependent asthma, cross-country skiers' asthma, elite athlete
asthma, infection-induced asthma, steroid-insensitive eosinophilic asthma, and
noneosinophilic (neutrophilic) asthma [241, 244, 245]. As research continues, and more
endotypes are elucidated and further classified, this effort advances asthma classification
towards personalized medicine [246].
Neutrophilic airway inflammation in asthma
Allergic asthma is the classic form of persistent asthma, and has been investigated
in great detail. Typically it has a childhood onset and is accompanied by allergic features,
including sensitization to allergens and allergic rhinitis[241]. The inhalation of allergens
by a predisposed individual triggers TH2 immune deviation, driving eosinophilic
inflammation and tissue damage, and resulting in airway hyperresponsiveness and release
of inflammatory mediators. This causes the clinical signs, including acute
bronchoconstriction [21, 241], which are largely sensitive to corticosteroid use. Research
over the past two decades has focused on these allergic pathways and inflammatory
profile.
The development of allergic asthma consists of three phases: induction, earlyphase asthmatic reaction (EAR), and late-phase asthmatic reaction (LAR) [247]. The
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induction phase occurs after the patient is first exposed to an inciting allergen. The
allergen is then taken up by antigen presenting cells, and is presented to allergen-specific
T and B cells in the lymph nodes [248]. Activation of T helper cells by the antigen
presenting cells leads to the production of cytokines that regulate B cells in their
production of immunoglobulin (Ig) E [249]. Once IgE is synthesized, the antibodies
circulate in the blood before binding to high affinity receptors present on both mast cells
and peripheral basophils [250]. When a patient is reexposed, the allergens cross-link to
the bound IgE, which triggers the production and release of mediators such as histamine,
prostaglandins, leukotrienes, and cytokines [250], beginning the EAR. The early phase is
an immediate response that lasts approximately 30-60 minutes, and is characterized by
constriction of airway smooth muscle cells, vascular leakage, mucus production,
enhanced airway hyperresponsiveness, and recruitment of inflammatory cells [251]. The
late phase occurs 4-6 hours later, and is characterized by a second period of
bronchoconstriction, excessive airway inflammation, increased bronchiovascular
permeability, enhanced airway hyperresponsiveness, mucus secretion, and through
chronicity, airway remodeling [167, 252, 253]. Approximately half of allergic asthma
patients develop a late-phase response after allergen challenge [254].
Traditionally, it was thought that all asthmatics had allergic asthma, and
associated eosinophilic inflammation. However, more recent literature estimates that
greater than 50% of asthmatics have neutrophilic inflammation, correlating to more
severe disease [87-89]. The airways in severe asthma have been described as having
characteristics of a chronic wound, with evidence of on-going epithelial injury and repair
[255]. A cause of increased recruitment of neutrophils is through IL-8, a neutrophil
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chemoattractant, which is expressed in airway epithelial cells [256]. IL-8 is synthesized
and secreted is via epidermal growth factor receptor (EGFR) activation [257, 258], a key
factor of epithelial repair that is correlated to asthma severity [259]. The increased
recruitment and subsequent increased total number of activated neutrophils [260],
correlate with increased airway damage [261]. Further, with neutrophilic asthma, there is
a shift from the Th2 phenotype recognized in traditional allergic asthma to Th1-like
patterns with increased expression of tumor necrosis factor alpha (TNFα) [262] and
interferon-gamma (INFγ) [263]. TNFα also increases IL-8 synthesis [257], and itself can
increase chemotaxis of neutrophils [262, 264].
For an asthmatic to be considered part of the noneosinophilic, or neutrophilic
asthma endotype, they must have the following essential pathogenic mechanisms:
activation of the innate immune response, abnormal activation of histone deacetylase 2,
abnormal recruitment of neutrophils, increased survival of neutrophils [265] and
demonstrate reduced corticosteroid responsiveness [99]. The gold standard for diagnosing
neutrophilic asthma is through induced sputum measurements, with numbers of
neutrophils correlating to disease severity [266].
Mainstay therapies that are efficacious for traditional allergic asthma are not as
effective in patients with neutrophilic disease. As disease severity increases, and numbers
of neutrophils increase, corticosteroid refractoriness also increases [99]. Additionally,
treatment with corticosteroids has been shown to promote neutrophil survival, further
increasing the magnitude and duration of inflammation [267]. These treatment challenges
that accompany severe neutrophilic asthma highlight the need for suitable animal models
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to investigate the mechanistic basis of asthma that is accompanied by neutrophilic airway
inflammation.
Animal models of asthma
Complex multifaceted diseases such as asthma necessitate investigations at the
whole-organism level. Animal models of human disease address this need by allowing
researchers to examine differences in the complex in vivo interactions that characterize
diseased and non-diseased whole organ systems [233]. Animals have been used
extensively to study mechanisms of asthma, the activity of asthma related genes and
pathways, and to estimate safety of asthma therapeutics [268, 269]. These investigations
have produced much of the current knowledge regarding the mechanisms that are
responsible for asthma. However, the complexity of asthma, and the varying endotypes,
make finding an animal model that mimics all characteristics of disease difficult [270].
The four key characteristics of asthma, airway inflammation, reversible airway
obstruction, airway hyperresponsiveness, and airway remodeling, should be a minimum
standard in an animal model of asthma, along with exhibition of all clinical signs shown
by humans, including wheezing and coughing.
Many different animal models have been used to investigate asthma, including
mice, rats, guinea pigs, ferrets, rabbits, cats, dogs, pigs, sheep, nonhuman primates, cattle,
and horses, and each have their strengths and weaknesses. The most frequently used
models are rodent models [271]. The only two species to have spontaneous, natural
occurring asthma like syndrome are cats and horses [120], although dogs do have a
spontaneous, exercised induced form of disease. Each of these species has sequenced
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reference genomes of varied refinement that facilitate genome-based investigations [272281].
Murine model
Mice are the most popular animal for modeling allergic responses in the airways
[62, 271]. Many protocols are employed in murine models of asthma, but the most
common, traditional approach is using antigen sensitization via ovalbumin (OVA),
usually given intraperitoneally with an adjuvant, followed by an inhalation challenge
[233, 282]. This approach results in an acute asthma-like,Th2-like, inflammatory
response. Cytokines including interleukins 4, 5, 13, and 9, are released, promoting
eosinophilic inflammation. The importance of dendritic cells, Th2 cells and eosinophils
to the allergic response have been mapped out primarily using this mouse model [283].
More recently, researchers have attempted to develop "long term" mouse models
through repeated sensitization to OVA, or to multiple human allergens, such as house
dust mites [284], cockroach antigens [285], Aspergillus fumigatus [286], and ragweed
[287]. In these protocols, mice are continually exposed to antigen for up to 12 weeks.
Chronic models have been met with limited success, with development of tolerance to
antigen, resulting in diminishing airway inflammation and airway hyperresponsiveness
[288, 289]. This model fails to stimulate chronic inflammation and epithelial alterations,
both important characteristics of human asthma that are not present in rodents. These
models do yield a degree of airway remodeling, but it is largely due to fibrosis, and not
airway smooth muscle hypertrophy, which is the predominant histologic change that
correlates to worsening asthma severity in humans [290, 291].
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There are some advantages to the mouse model; mainly cost and convenience.
Mice are inexpensive to acquire, have a short and successful reproductive cycle, are easy
and inexpensive to house, and are easy to handle. There is also a wide availability of
genetically characterized inbred strains, at low cost, which allows for focused
mechanistic research, and examination of particular pathways and genes [292, 293], and
transgenic mice are useful to characterize key events and effector molecules that regulate
airway inflammation [293].
However, it is important to note the significant disparity that exists between
antigen sensitized mice and human asthma. Not only must the disease phenotype be
induced in the mouse [233], but their response is strictly allergy-based with a
predominance of eosinophilic inflammation, and does not provide information of
relevance to severe, neutrophilic inflammation. Sensitization via ovalbumin injection is
completely different from the naturally occurring human disease in which sensitization
occurs via the respiratory tract, and OVA does not trigger asthma in humans [294]. Even
after sensitization, an OVA-mouse does not truly develop asthma, but demonstrates
certain cellular and pathophysiological features that have some similarities to parts of the
asthma condition, namely a massive influx of inflammatory cells, particularly
eosinophils, airway hyperresponsiveness, and an IgE response [283]. Further, strains of
mice can exhibit vast differences in the extent to which they develop immune responses
to the same sensitizer [295], with levels of antigen-specific IgE varying between strains
[296], as well as differences in the degree of eosinophilic inflammation, airway wall
thickening, collagen deposition, and airway hyperresponsiveness [295, 297]. Like other
laboratory animals, mice are housed in clean and controlled laboratory environments
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where they are not exposed to the same environmental allergens that contribute to disease
in humans [283].
Mice also have well-documented disparities in the branching pattern, airway
smooth muscle mass, and type and location of inflammatory cells relative to human
asthma [298]. Histologic abnormalities are also largely isolated to airways in humans, but
mice also show lung parencyhmal and pleural involvement [299]. Humans and mice also
have different transcriptional responses to acute inflammatory insults [300], which limit
direct translation of results. For example, mice lack the gene that codes for interleukin-8
[301], a neutrophil chemotactic factor which has been implicated in severe asthma [88].
One of the most important differences between humans and mice is that antigen
responsiveness in mice is not persistent [302]. That is, when the allergen exposure ceases,
the inflammatory process, and airway hyperreactivity abate, and require an additional
sensitization period to re-establish airway inflammation and hyperresponsive to antigen
challenge. In humans, these facets of asthma persist despite extensive periods of antigen
withdrawal [80].
While it is now recognized that the original concept of asthma as a Th2-mediated
disorder is overly simplistic, and that the mouse model fails to appropriately model the
asthma syndrome, mouse models continue to be the primary model used to evaluate new
therapies [283]. It is now generally recognized that mice are suitable for modeling traits
associated with asthma, rather than modelling the entire asthma syndrome, or even a
specific endotype [269]. Alternative murine models are being used and developed,
including models demonstrating limited biphasic inflammatory responses and
neutrophilic inflammation. Models with two different asthmatic phases have used
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sensitization protocols with cockroach antigen [303] and chronic intratracheal ovalbumin
[304, 305]. In 2012, Vaickus et al. demonstrated an early airway response occurring 1.5
hours post-challenge with cockroach antigen, and a second phase occurring 24 hours
later. The first phase was characterized by inflammatory mediators such as CXC
chemokines, mucin production, and recruitment of neutrophils to the lung, and the second
was characterized by accumulation of new mucin in pulmonary epithelial cells;
eosinophils remained constant throughout the study [303]. Nabe et al. (2005) established
a late-phase model with airway obstruction that peaked at 30 minutes, and returned at 2-8
hours. Their study required four intratracheal exposures to ovalbumin [305]. The 1st
through 3rd challenges resulted in airway inflammation characterized by infiltration of
eosinophils and CD4+ cells, while the 4th challenge induced neutrophilic inflammation
into the airway [305]. These two investigations are representative of the current
information regarding late-phase allergic responses in mice, where additional
investigations are needed to address these somewhat contradictory findings regarding the
timing and inflammatory profiles of the late phase reaction in this species.
Rat model
Rats are also popular models of allergic airways disease. In the past, rats were
used more frequently to model asthma, but in recent years, mouse genetics and associated
technologies have improved exponentially, increasing the popularity of the mouse as a
model [271]. Just as in mice, the asthma-like disease exhibited by rats can only be
induced, and they are easily sensitized to antigens such as ovalbumin, house dust mites,
and Ascaris [306, 307]. Challenge results mostly in a Th2-like response, with
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predominant airway eosinophilia and IgE [308], but there can be involvement of
neutrophils, mast cells, and lymphocytes [309-311].
Neutrophilic inflammation can occur in rat models of asthma, but there are
variations between strains. In Brown Norway rats subcutaneously OVA-sensitized,
challenge with aerosolized OVA results in neutrophilia present 3-14 hours after
challenge, followed by a peak in neutrophilia and initial evidence of eosinophil
infiltration at 24 hours post-challenge [309, 312]. Another common mechanism to induce
neutrophilic pulmonary inflammation in Sprague-Dawley rats is via intranasal LPS
sensitization and challenge [313, 314].
The popular rat model has some distinct advantages. Key facets of asthma,
including airway hyperresponsiveness, airway inflammation, and airway obstruction can
be easily reproduced in rats [311, 315]. Other similarities between rats and humans
include immediate and late asthmatic responses after a nonspecific challenge with
methacholine, acetylcholine or serotonin, IgE production, and inflammatory cell
accumulation [311, 316]. Recent studies on OVA sensitized rats with long term challenge
with either inhaled Aspergillus fumigatus or ovalbumin, demonstrated airway remodeling
changes including goblet cell metaplasia, airway smooth muscle hypertrophy and
hyperplasia, collagen deposition, and epithelial cell damage, along with increased airway
responsiveness and inflammation [315, 317, 318]. Compared strictly to mice, rats have a
size advantage, making measurement of physiological outcomes such as airway
hyperresponsiveness and acute responses to allergens easier to obtain. Finally, like other
small laboratory animals, rats are inexpensive and easy to handle and care for.
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Disadvantages of the rat as an animal model are similar to those in the murine
model. Most significantly, disease is not spontaneous and must be induced with antigens
and adjuvants. There are many strains available, and response following sensitization and
challenge varies between strains [309, 310]. Finally, when compared to the mouse,
species-specific immunological reagents are not as abundant [319].
Guinea pig model
Although mice are the most common animal used to model asthma, beginning
more than 100 years ago, guinea pigs were the original animal model of asthmatic disease
[268]. Like mice and rats, guinea pigs must also undergo antigen sensitization protocols
to develop asthma-like disease. Guinea pigs are readily sensitized to OVA, and
accordingly most guinea pig models involve serial intraperitoneal injections of OVA
[320, 321]. Other antigens have been used to induce experimental asthma, including
intramuscular injections of bovine serum albumin [322], intradermal injections of
trimellitic anhydride (TMA) [323], and cockroach antigens [324]. There are also chronic
sensitization protocols involving a longer, month-long OVA sensitization period that
result in some airway remodeling changes [320].
Histologically and clinically, the guinea pig model has similarities to human
asthma [325, 326]. Guinea pigs exhibit bronchoconstriction, cough, airway
hyperresponsiveness, inflammation, and remodeling with exposure to antigen [327].
Airway remodeling changes from chronic OVA challenge include increased smooth
muscle mass, epithelial thickness, bronchiolar collagen, and goblet cell hyperplasia [320].
Guinea pigs develop both early and late asthmatic responses, where both eosinophilic and
neutrophilic inflammation can be observed [326, 328]. Guinea pigs are a preferred model
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for evaluating anti-asthmatic drugs in allergic bronchial asthma, due to similarities in
their airway anatomy and response to inflammatory mediators [329]. Guinea pigs are
small, docile, inexpensive and easily handled, but large enough for researchers to isolate
portions of airways for testing.
Guinea pigs have limitations as a model of asthma. Significantly, the asthmatic
condition in guinea pigs must be induced by antigen sensitization [329]. There is also a
scarceness of genetically modified animals, inbred strains, and guinea pig-specific
reagents [271].
Rabbit model
Rabbits have been used as a model of asthma since the 1970s, although overall,
they are infrequently used. Like prior models, in rabbits the asthma-like disease can only
be induced following a sensitization protocol, and is not a spontaneous disease. Pinckard
et al. (1977) was the first to sensitize rabbits. Their protocol included weekly
intraperitoneal injections of neonatal rabbits with bovine serum albumin in conjunction
with Corynebacterium parvum adjuvant [330]. This results in production of antigenspecific IgE [331], and exhibition of airway signs following aerosol challenge. Since the
1970s, this protocol has been modified to include a number of various antigens for
sensitization, predominantly ovalbumin [332] but also including ragweed [333], house
dust mite [334], horseradish peroxidase [335], Alternaria tenuis [336], or even a
combination of antigens [337].
The rabbit model has considerable advantages over traditional rodent models,
with its larger size allowing for easier lung function testing, nonlethal monitoring of
physiological changes, and sample collections, including bronchoalveolar lavages [338].
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Rabbits are easy to handle and readily available [339]. Furthermore, the ability to
sensitize the rabbits at birth, and follow them through to adulthood allows researchers to
investigate processes that contribute to development of allergic disease [331]. With
chronicity, airway remodeling also occurs, with thickening of the epithelial layer,
mucosa, and submucosa of the lung [340]. Like the human allergic asthma endotype,
rabbits exhibit airway hyperresponsiveness, and demonstrate both acute and late phase
reversible airway obstruction, as well as eosinophilic inflammation [336, 338, 341].
However, if rabbits are not immunized as neonates, the late phase airway responses that
are present in a majority of human asthmatics do not occur [331, 339]. Additionally,
rabbits lack submucosal glands and their goblet cells are less abundant than in humans
[342]. Rabbits are also more costly than the traditional rodent species used to study
asthma, and require more space for housing [331]. Tools and reagents to use in rabbits, as
well as knock out or transgenic rabbits, are also less available [331, 339].
Canine model
Dogs have been extensively used to investigate asthma. Although dogs readily
develop spontaneous allergic disorders, they typically manifest themselves as dermatitis,
not asthma [343]. Rarely, and unlike most animal models, spontaneous asthma-like
disease does occur in dogs. The syndrome occurs in specific environments: Alaskan sled
dogs in subzero temperatures [344], and dry air environments [345], and is exerciseinduced. These would likely be superb models for the cross-country skiers' asthma and
elite athlete asthma endotypes, respectively, but are not as useful for studying severe
asthma. Most canine studies employ an induced model of disease; performed using
aerosol sensitization to Ascaris suum larvae [346, 347] or neonatal sensitization to
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ragweed [348]. Although the exercise-induced disease of dogs is useful as a model of
certain exercise-induced human asthma endotypes, the canine Ascaris suum model is not
a naturally occurring disease process like that of asthma in humans. It is interesting that
Ascaris suum, the roundworm of pigs, and Ascaris lumbricoides, the round worm of
people may indeed be a single or very closely related species, and that Ascaris suum can
attain patent infections in both dogs and humans, making this model of unique relevance
in asthma investigations [349, 350].
There are many benefits to using a canine asthma model. Following sensitization,
many key features of human asthma, including reversible airflow obstruction,
inflammation, mucus hypersecretion, airway hyperresponsiveness, and cough are
demonstrated [348, 351]. Similar to severe asthmatics, pulmonary inflammation consists
mainly of neutrophils [352-354], though it can also be eosinophilic [353, 355]. As in
human asthma, the canine syndrome affects both central and peripheral airways, with
constriction of both central and distal airways [356]. Additionally, their relatively large
size and easy handling is ideal for repeat bronchoscopies and procedures that involve
mapping the airways or long-term exposure to allergens [357].
The canine model is not a perfect model for human disease and has distinct
disadvantages. With exception of the exercise-induced form of canine asthma, the disease
must be induced from chronic antigen sensitization. When sensitized, dogs predominantly
exhibit an acute phase response, as the presence of a late-phase response is not routinely
found after antigen challenge [348, 357]. The acute phase is characterized by airway
constriction [358], including peripheral airway constriction [359], mucus hypersecretion
[360], tachypnea [361], and a sensitized cough reflex [362]. The late phase can be
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reliably produced using a wedged bronchoscope method to deliver antigen directly to the
airways [363]. Further, airway remodeling has not been extensively investigated with the
canine asthma model. However, in canine models of COPD with long-term exposure to
sulfur dioxide gas, hypertrophy and hyperplasia of airway mucus glands, thickening of
the airway epithelium, mucus hypersecretion, airway smooth muscle thickening, and
airway wall thickening have been observed [364, 365]. Genetically manipulated canine
lines are rare. While this is considered a disadvantage in research, it is relevant that
asthma is a multifactorial disease that reflects complex genetic and environmental
interactions. Accordingly, spontaneous asthma-like diseases in outbred animal
populations, such the spontaneous disease of sled dogs, are powerful and valid models in
which the complex interaction of environment and genetics responsible for asthma can be
investigated. Particular disadvantages of the dog include limited immunologic reagents,
and as a larger animal species, increased animal, housing, and maintenance costs [271].
Ovine model
Sheep have been used to study asthma both through inducible allergic responses
to house dust mite [366] and through natural sensitization to Ascaris suum [367].
Sensitization protocols involving house dust mite generally involve a subcutaneous
injection protocol [366]. In sheep, inhalation of antigen elicits early and late-phase
bronchoconstriction and airway hyperresponsiveness [368, 369], accompanied by
eosinophils, neutrophils, and lymphocytes [367, 370].
Additionally, sheep have structural similarities to human lungs, allowing the use
of methodologies and equipment used for pulmonary function testing in humans. The
branching pattern and size allow repeat bronchoalveolar lavages or biopsies, and accurate
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measurement of pulmonary function [367]. Alveoli, airway size, cartilage distribution,
sensory nerves, capillaries, collagen, bronchial glands, and goblet cells are similar to
humans [367]. Lung function is also similar, including airflow, resistance, breathing
rates, tidal volume, and compliance [371]. Sheep also develop wheezing and coughing in
response to antigen sensitization and challenge. Chronic HDM sensitization protocols
result in airway remodeling changes including increased collagen, airway smooth muscle
proliferation, goblet cell hyperplasia, and epithelial cell hyperplasia [369, 370].
A 2008 study with chronic A. suum challenge demonstrated irreversible
bronchoconstriction that was nonresponsive to albuterol, a finding that is more consistent
with human COPD than asthma [367]. Other limitations to using the induced asthma-like
disease in sheep include a lack of inbred and genetically manipulated sheep, and very
limited immunologic reagents [371]. Additionally, like other large animals, animal costs,
housing, and maintenance become progressively higher with increasing animal size.
Non-human primate models
Approximately fifty years ago, researchers began to use rhesus monkeys
sensitized to Ascaris suum, an intestinal parasite, to study allergen-induced airway
responses [372]. Ascaris exposure promotes an IgE and a Th2-like immune response
[373], and subsequent airway challenge results in immediate and late phase asthmatic
reactions, as well as eosinophilia and hyperresponsiveness [374, 375]. Other non-human
primate models for allergic asthma have been developed in rhesus and cynomolgus
monkeys using human allergens such as house dust mite and birch pollen antigens [376,
377].
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There are many advantages to using nonhuman primates as a model of asthma.
Monkeys are genetically and physiologically similar to humans, with similar pulmonary
anatomy, histology, and size. Human protein and monoclonal antibody therapeutics can
be studied because of the close similarity of species [378], and they are therefore the most
suitable asthma model for investigating immune regulation and to test new
immunomodulatory therapies in asthma [379]. Additionally, the innervation of airways in
monkeys is similar to that of the human [380]. Clinical signs such as coughing and
dyspnea, as well as all four hallmark features of human allergic asthma are observed in
nonhuman primate models, including airway obstruction, eosinophilic airway
inflammation, airway hyperresponsiveness, and airway remodeling through goblet cell
hyperplasia, epithelial hypertrophy, and thickening of the basement membrane [377,
379]. Airway smooth muscle hypertrophy and hyperplasia was also noted in chronically
sensitized monkeys [381]. Both an acute and late-phase bronchoconstrictor response is
present in monkey models [374].
Despite those advantages, the nonhuman primate model has limits. Most
significantly, nonhuman primate asthma models are induced, and are not completely
representative of the spontaneous process of disease in humans. Airway inflammation is
predominantly eosinophilic [382], making monkeys a poor model for severe neutrophilic
endotypes of asthma. There is also a large expense for care for the animals, food, medical
care, and housing. Further, there is a great deal of effort required to maintain the model,
as sensitization develops over 18 months and requires frequent handling of animals to
continue exposure to antigens [382]. Further, many ethical issues surround the use of
captive primates.
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Feline model
Cats have a spontaneous form of asthma, called "feline asthma syndrome," which
makes the feline model an interesting and valuable model for asthma research [383].
Diagnosis of feline asthma is generally made from a combination of clinical signs,
radiographic findings, and response to treatment [384]. Radiographic signs of disease
include bronchial wall thickening and increased bronchial or interstitial lung patterns
[385]. Most affected cats respond quickly to bronchodilators or steroids such as
prednisolone.
The feline model has many advantages compared to other asthma models; most
notably that it is a spontaneous disease. Feline asthma also has many immunologic,
physiologic and pathologic similarities to human asthma, including reversible airway
obstruction, airway hyperresponsiveness, airway remodeling, airway smooth muscle
thickening, goblet cell hyperplasia, allergen-specific IgE, and eosinophilic airway
inflammation [380, 386]. There are also clinical similarities between feline and human
asthma, including recurrent episodes of coughing, wheezing, and dyspnea [385, 387,
388].
However, there are some disadvantages to using cats to study asthma. In general,
cats do not handle respiratory distress well, and limited interventions can be tolerated
[388]. Genetic and molecular tools are underdeveloped for feline models [380]. The
eosinophilic response of cats makes them an excellent, naturally occurring, model of
allergic asthma, but as the predominant inflammatory cell type is the eosinophil, they are
not a suitable model for the neutrophilic asthma endotype. Although cats experience an
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obvious acute response to allergens, characteristics of the late phase response are not well
characterized in cats.
Equine model
Horses spontaneously develop a chronic respiratory disease, recurrent airway
obstruction (RAO), which is triggered by aeroallergens including dust and hay [389-391].
Two separate disease syndromes have been described. Traditional RAO, which mainly
occurs in temperate climates [389], and pasture heaves which generally occurs in hot and
humid climates [392, 393]. Occasionally horses can be affected with both forms of
disease [393]. Horses must be predisposed genetically, and be exposed to certain
environmental events for disease to occur [394]. In RAO-affected horses, disease is
reliably triggered by challenge with moldy hay, and is typically associated with increased
aeroallergen exposure coupled with inadequate air circulation [395]. Exacerbation is
particularly common when horses are housed in stalls and barns with poor air quality,
with poor quality, dusty, or moldy hay [396]. Inhalation of pollens and outdoor molds are
thought to be the main cause of the summer condition [397], but clinical exacerbation is
also associated with increases in temperature and humidity [398].
Both forms of disease are useful as models for severe, neutrophilic asthma. Like
human asthmatics, horses have clinical signs that range in severity from exercise
intolerance to coughing, wheezing, tachypnea and dyspnea [397]. All four key facets of
human asthma are demonstrated in the RAO model, including chronic airway
inflammation, airway hyperresponsiveness, reversible airway obstruction, and airway
remodeling [396, 399-402]. The same facets are present in the pasture heaves model, and
airway hyperresponsiveness has also been experimentally documented [403]. With both
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diseases, affected horses have goblet cell metaplasia and hyperplasia, smooth muscle
proliferation, airway fibrosis, and mucus hypersecretion [120, 399, 404, 405], all of
which are changes present in the asthmatic airway. Airway inflammation is primarily
neutrophilic, but some horses can present a moderate eosinophilic airway infiltration
[406]. Horses have a long lifespan on the scale of 25-30 years which allows researchers
to investigate disease progression over years, even decades [407]. The effect of aging on
immunological models is disregarded with rodent models, but both innate and adaptive
immune functions change with age [408]. Further, RAO is a disease of middle aged to
older (>20 years) horses, and horses that are 7 years of age or older are 6-7 times more
likely to develop RAO than younger animals [409]. Ages are similar for pasture heavesaffected horses; Costa et al. (2009) noted a median age of 15 years in the horses involved
in their study [410]. This is in keeping with adult forms of asthma in which neutrophilic
airway inflammation predominates [87-89]. Finally, like other large models, the size of
horses allows for easier sampling, including pulmonary function testing [402, 411],
methacholine challenges [403, 411, 412], lung lavages [401], and bronchial and lung
biopsies [413].
Although the horse is the most complete model for investigating the human
asthma syndrome, especially the neutrophilic disease endotype, using horses as an
animal model is not free of drawbacks. Immunological reagents are limited for use in the
horse, including availabilities of antibodies [414]. Due to their size, drugs, facilities,
equipment, veterinary care, and food has a higher cost. However, an equine tissue bank
has been developed for respiratory research, so researchers lacking the facilities and
funding to keep a research herd of horses can still study this model [401].
51

Recurrent airway obstruction and pasture heaves
Horses naturally develop a chronic, asthma like disease called "recurrent airway
obstruction," (RAO), also known as "heaves." RAO is a spontaneous allergic respiratory
disorder affecting mature horses, with exacerbations of acute airway obstruction followed
by periods of remission [415]. Two syndromes have been described. Traditional RAO, or
barn-associated RAO, which occurs commonly in temperate climates [389], and pasture
heaves, also known as summer pasture associated recurrent airway obstruction
(SPARAO), which occurs in hot, humid climates such as the Southeastern United States
and the United Kingdom [392, 393]. Horses can infrequently be affected by both forms of
disease [393]. Affected horses, during disease exacerbation, exhibit respiratory distress
episodes similar to those affecting asthmatics, ranging in severity from exercise
intolerance and coughing to tachypnea, dyspnea, and wheezing. Like human asthmatics,
RAO is characterized by chronic airway inflammation, airway obstruction, and airway
remodeling [393, 397]. Airway obstruction results from accumulation of mucus,
inflammation, and bronchoconstriction. Both RAO and pasture heaves have previously
been called chronic obstructive pulmonary disease (COPD), but this term has been
discarded, as human COPD has minimally reversible airway obstruction and airway
hyper-reactivity is not a predominant facet of disease [416].
RAO is the most common chronic respiratory condition affecting mature horses
housed in the barn in the northern hemisphere [391], but only occurs rarely in warm and
dry climates such as California and Australia [389]. In 1998, an epidemiological study
estimated that RAO affected 43% of winter stabled horses [417]. Risk factors of disease
include increased aeroallergen exposure coupled with inadequate air circulation, direct
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exposure to aeroallergens, or stalls and barns with poor air quality, with poor quality,
dusty, or moldy hay [396]. Disease is reliably triggered by challenge with organic molds
found in hay, and clinical signs can be alleviated by reducing dust exposure and
improving ventilation in the stall [395]. Risk is also associated with increasing age.
Horses that are 7 years of age or older are 6-7 times more likely to develop RAO than
younger animals [409]. Exposure to urbanized environments with air pollution is also a
risk factor for RAO [392].
Opposite of traditional RAO, pasture heaves is reported in mature horses housed
on pasture during spring and summer months, with disease remission occurring during
the winter [418]. Inhalation of pollens and outdoor molds are thought to be the main
cause of the summer condition [397], but clinical exacerbation is also associated with
increases in temperature and humidity[398]. Mature horses that are kept on pasture for
more than 12 hours a day are more likely to develop pasture heaves [419, 420]. For both
diseases, clinical remission occurs when horses are removed from the inciting
environmental allergens [389, 397].
Both syndromes are heterogenous diseases that result from a predisposing genetic
factor and environmental interactions [394]. The precise immunopathological
mechanisms and antigens responsible for causing the clinical syndrome in susceptible
animals have not been determined[390, 402]. As with asthma endotypes that group
asthma by the respect underlying pathophysiologic mechanisms, this likely reflects a
complex multifactorial pathophysiology that varies among subsets of horses with both the
barn and pasture associated diseases. Intradermal tests have confirmed hypersensitivity to
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numerous antigens, but skin hypersensitivity does not necessarily signify a causal
relationship for RAO [395].
RAO and pasture heaves-affected horses present with similar clinical signs, which
result from airflow obstruction, which occurs secondary to diffuse bronchoconstriction
[391]. The most common signs are flared nostrils, tachypnea, coughing that worsens
during exercise, intermittent serous nasal discharge, exercise intolerance, and anxiety. A
heave line, reflecting hypertrophy of the external abdominal oblique muscle is evident in
the most severely affected horses [416]. In RAO, clinical signs are associated with horses
stabled during the winter months, but pasture heaves clinical signs first appear during
spring months, becoming more prominent during late summer, and entering remission
during the winter [420].
Pathophysiology
Similar to human asthma, pasture heaves and RAO are characterized by four key
components: reversible airway obstruction, airway remodeling , airway inflammation,
and airway hyperresponsiveness [396, 398-402, 421, 422].
During disease exacerbation, the major cause of airflow limitation is diffuse
bronchoconstriction, but mucus plugs, inflammatory cells, and airway remodeling are
also components of obstruction [391, 423]. After bronchodilators are administered to
horses, there is a rapid improvement of 60-70% in lung function, indicating the
reversibility of a majority of obstruction [399, 424]. This is significant to the viability of
equine RAO/pasture heaves as a model of asthma, as the diagnosis of human asthma
hinges upon the diagnosis of reversible airway obstruction. Airway smooth muscle is the
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cell type predominantly responsible for the rapid constriction of airways [425], and is a
key cell type in both asthma and equine RAO/pasture heaves [20,27].
Airway remodeling in affected horses is multifaceted, and includes goblet cell
metaplasia and hyperplasia, airway smooth muscle proliferation, airway fibrosis, and
mucus hypersecretion; all of which are present in asthmatic patients [120, 399, 404, 405,
426]. Furness, et al., (2010) demonstrated metaplasia of goblet cells in noncartilaginous
airways of RAO-affected horses [427]. Costa et al. (2000) followed by Polikepahad et al.
(2008) also confirmed the presence of goblet cell metaplasia in noncartilaginous airways
of pasture heaves-affected horses [406, 426]. Herszberg, et al., (2006) and Mujahid, et
al., (2011) used histomorphometry to demonstrate that RAO and pasture heaves,
respectively, are characterized by an important increase of airway smooth muscle in
small and large airways [400, 405]. Additional research is warranted to clarify the degree
to which airway smooth muscle proliferation contributes to airway remodeling and how
this process occurs in RAO. Mucus hypersecretion is an important feature of both RAO
and pasture heaves, and it is even present during times of disease remission [399, 428].
Mucus accumulation in the airways of both RAO and pasture heaves-affected horses also
contributes to exacerbation of clinical signs, as well as neutrophilic inflammation [399,
426, 429]. Costa, et al., (2000), described mucus accumulation as the main change in
small airways of pasture heaves-affected horses [426] and Polikepahad, et al., (2008) also
suggested that the most prevalent histopathologic change in euthanized pasture heavesaffected horses is mucus accumulation [406]. Pulmonary fibrosis has been described in
RAO using light microscopy and electron microscopy [430], but the collagen types
involved have not been determined [431].
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The inflammatory process in RAO and pasture heaves is characterized by a
predominance of neutrophilic infiltration, which can vary in severity [419, 432]. A minor
and occasional eosinophilic infiltration may also be present in RAO horses [428]. Airway
neutrophils are recruited 3-6 hours after allergen exposure, and are more numerous in
RAO-affected horses compared to controls exposed to the same environment [433]. RAO
is also characterized by delayed apoptosis of neutrophils, and neutrophil release of
elastase, oxygen metabolites, LTB4, and MMP-9 [433-436]. Cytokines such as IL-1B,
TNF-a, IL-8, and IL-17 are all increased in RAO affected horses, which are likely
partially derived from neutrophils [437-440]. Chronic immune activation is present in
neutrophilic human asthma, as in RAO, which persists during remission of disease [441,
442].
Inflammatory mediators including histamine, bradykinin, nitric oxide (NO), and
endothelin-1 (ET-1) are increased during disease exacerbation in pasture heaves horses
[421, 443]. NO, an inflammatory mediator with implications in the development of
airway inflammation in human asthma, is derived from inducible NO synthase (iNOS) in
airway epithelial cells [444]. Costa et al. (2001) examined the plasma and BALF
concentrations of NO and localization of iNOS in pasture heaves horses and found an
increase in plasma NO concentration in pasture heaves horses that was not statistically
relative to non-diseased control horses [48]. However, iNOS production in bronchial
epithelial cells from 3 of 5 lung lobes was significantly elevated in pasture heaves relative
to control horses, suggesting that NO may have a role in amplifying the inflammatory
response at the surface of airways. Airway hyperresponsiveness is present and is
increased when affected horses are exposed to dust, even before changes in lung function
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and clinical signs can be observed [445]. One mechanism of airway hyperresponsiveness
in pasture heaves horses is mediated by airway sensitivity to endothelin-1, a potent
contractor of equine bronchi that is increased in plasma and pulmonary secretions during
exacerbations of pasture heaves [410]. Increased ET-1 sensitivity in has also been
documented by increased ET-1 receptor expression in bronchial smooth muscle of horses
with pasture heaves [22]. In humans, ET-1 is produced by many cells in the body, but the
lungs are the primary site of synthesis; the greatest concentration being found in smooth
muscle and alveolar septae [446]. The known functions of ET-1 include maintenance of
airway tone [415], smooth muscle contraction [415], bronchodilation through the release
of prostaglandin E2 from airway epithelium [421], and potent bronchoconstriction
through the release of secondary mediators including thromboxanes and platelet
activating factor [447]. ET-1 also stimulates DNA synthesis in airway smooth muscle,
resulting in proliferation[447], and has proinflammatory effects on airways, including
activation of cytokines [448]. ET-1 levels are increased in BALF and plasma of human
asthmatics [449] and horses with RAO [415]. Accordingly, ET-1 is an important
contributing factor to airway smooth muscle constriction in pasture heaves, and likely to
RAO as well.
The persistence of airway hyperresponsiveness in RAO-affected horses has been
debated within the literature. Studies have shown that clinically normal, RAO-affected
horses kept in low-dust, indoor, controlled environments have persistently
hyperresponsive airways when compared to healthy controls housed in the same
environments [411, 423, 450]. However, of those studies, one noted higher clinical
scores in the RAO-affected group [423]. In direct contradiction of this, other studies
57

have indicated that airway hyperresponsiveness does not occur when RAO-affected
horses are on pasture, in clinical remission [396, 412, 451]. A hyperresponsive reaction
occurs in RAO horses in response to non-specific agonists such as histamine [452-454]
and methacholine[412]. This persistence of AHR is an important facet of RAO as an
animal asthma model, as AHR does not persist in induced murine models of asthma
[302].
Pathogenesis of RAO and pasture heaves
The pathogenesis of RAO has been more heavily investigated than that of pasture
heaves. It is generally accepted that there is a hypersensitivity component to RAO
pathogenesis [389], but compared to other allergic diseases, the underlying
immunological mechanisms of RAO are more complex [455], involving both innate and
adaptive immunity[456]. The role of IgE in RAO is controversial, with conflicting results
within the literature. Some studies showed an increase in serum IgE concentration in
RAO horses [457, 458], while other studies showed no significant difference [432, 459],
including in bronchoalveolar lavage fluid (BALF) samples [457]. Scharrenberg et al.
demonstrated through a genetic study of offspring from two RAO-affected sires that
allergen-specific IgE concentrations were higher in offspring of one sire when compared
to the other, indicating a genetic effect on allergen-specific IgE levels [460]. Genetic
differences and the presence of groups of horses that share similar pathophysiologic
mechanisms, akin to the description of endotypes in asthma, may help explain some of
the differences within the literature, as many studies contain small sample sizes of
genetically outbred horses. Dirscherl et al. demonstrated that relative to control horses,
basophils from affected horses were hypersensitized to many antigens, including molds
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of the genus Mucor [461]. This work substantiates a role for IgE-sensitized inflammatory
cells in some horses with RAO, as the gateway to antigen-specific recognition and
initiation of the inflammatory cascades, and is consistent with a similar IgE mediated
endotype in asthma [reference here for IgE mediated asthma]. Further, in vitro
stimulation of basophils and pulmonary mast cells is an accepted method of identifying
allergens involved in RAO pathogenesis [462-465].
Following exposure to allergens, RAO-affected horses develop airway
inflammation characterized by a massive influx of neutrophils [466], and an increase in
CD4+ cells in BALF [467, 468]. Helper T cells orchestrate the inflammatory response in
RAO, and the intensity of cytokine expression has been correlated to disease chronicity
[466]. Cordeau et al. demonstrated that relative to unaffected horses, RAO-affected
horses had increased mRNA expression of IL-4 and IL-5, and decreased expression of
INF-γ, which is a predominant Th2-type cytokine response, coinciding with the presence
of airway obstruction [469]. This is consistent with the Th-2 cytokine profile that has
been demonstrated in allergic asthma endotypes [470]. However, characterizing the
cytokine profile of RAO into a predominantly Th2 or Th1-mediated response has been
difficult, as studies have generated contrasting data. Ainsworth et al. showed the cytokine
profile of RAO horses, compared to unaffected horses, had increased expression of INFγ, but decreased IL-4 and IL-13 in BALF cells [437]. This cytokine profile is consistent
with a Th1-type cytokine response, which is more similar to the cytokine profile seen in
the neutrophilic endotype of human asthma [263]. Some studies on RAO-affected horses
have even demonstrated a mixed response, with increased mRNA expression of IL-4, IL13, and INF-γ in BALF [438, 471]. The disparity in results could be related to differences
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in the clinical stages of the horses and timing of sample collection [468, 471, 472]. In
addition, horses with RAO have decreased pulmonary clearance [10211695] and the
possibilities of confounding subclinical infection in these populations should be
considered. In 2005, Debrue et al. showed that organic dust exposure increases gene
expression of IL-17, another T-cell derived cytokine, in the BALF of RAO-affected
horses, but not in unaffected horses [440], which may contribute to airway neutrophilia.
However, gene expression of IL-8 is also increased several days before IL-17 levels
become increased, making it a likely contributor to neutrophilia, at least in earlier stages
of RAO [437]. Continued research into the underlying pathogenesis of RAO will likely
divulge further information on T cell associated immunological mechanisms. It is clear,
however, that T cells play an important role in the pathogenesis of RAO, and one major
consequence of their activation is the recruitment of neutrophils into the airways.
Increases in specific disease mediators, including chymase, mucin, and
endothelin-1 (ET-1), are correlated with the changes seen during disease. A correlation
between high chymase positive mast cell numbers in the bronchial wall and lung fibrosis
has been demonstrated [432], suggesting a possible involvement in the airway
remodeling associated with RAO. The amount of stored mucin in goblet cells has been
shown to increase with severity of airway inflammation in RAO [404]. ET-1, a powerful
smooth muscle constrictor and proinflammatory mediator, is increased during RAO
exacerbation [415]. This finding has been corroborated in pasture heaves, with increased
ET-1 concentrations in plasma, BALF, and pulmonary epithelial lining fluid from pasture
heaves affected horses during seasonal exacerbation relative to other control horses, and
also to their own ET-1 concentrations during disease remission [406, 410, 421]. Other
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inflammatory markers in the airways of RAO horses include myeloperoxidase (MPO),
metalloproteinases (MMPs), ascorbic acid and associated markers of oxidative stress.
MPO, a neutrophil-derived enzyme, has been found to be increased in RAO-affected
horses when compared to control horses, both during disease exacerbation and remission
[473]. MMPs including MMP-1, MMP-8, MMP-9, and MMP-13 have been shown to be
elevated in BALF and tracheal secretions of horses with RAO during exacerbation, while
MMP-2 and MMP-14 have not [474-477]. It is hypothesized that the MMPs that differ
between groups may contribute to lung dysfunction in RAO horses, and can be used as
diagnostic markers of disease [477]. There are low ascorbic acid concentrations in BALF,
which result in the decreased antioxidant capacity of RAO horses compared to control
horses [478, 479]. In pasture heaves-affected horses, iNOS, responsible for the
production of the inflammatory mediator NO, is increased in airway epithelial cells [443].
Markers of oxidative stress, including oxidized glutathione concentrations, glutathione
and ascorbic acid redox ratios, and hydrogen peroxide, have also been identified as
increased within the airways and exhaled breath of RAO horses during disease [480-482].
Diagnosis and treatment
In 2011, Kutasi et al. determined that gathering a history and performing a
physical examination were not enough to accurately diagnose chronic pulmonary
disorders including RAO, yet veterinarians often do not use any tests to confirm
diagnosis [483]. The most useful combination of information to accurately diagnose
pulmonary allergic diseases in horses includes age of the horse, history, physical
examination, respiratory tract endoscopy, and BALF with cytologic analysis [483].
Cytologic analysis of BALF is simple and inexpensive, and can be used to differentiate
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between pulmonary infections and inflammation [484]. Horses with RAO/pasture heaves
typically have greater than 25% neutrophils present on cytology [426, 485].
Immunological testing has been a topic of debate within the literature, with some studies
showing an increased frequency of skin responses in RAO-susceptible horses following
intradermal injections of stable dust, mold extracts, and allergens [395, 486], but
conflicting results from other studies [390, 487] . The diagnostic value remains
questionable, and is significantly less valuable in a clinical setting than the recommended
diagnostic methods. While measures of lung function including resistance, compliance
and elastance are evaluated in airway research involving RAO and pasture heaves, the
equipment necessary to evaluate lung function is not well suited to its use in field practice
[391].
Prognosis depends on disease severity at time of diagnosis, and vigilant
environmental management. Though RAO and pasture heaves are chronic and
progressive, environmental management and medical therapy, including ß2-adrenoceptor
agonists and corticosteroids, can be effective in controlling clinical signs [423]. Second
line treatments, including anticholinergic bronchodilators such as atropine and
glycopyrrolate, and ipratroprium, and the methylxanthine bronchodilator theophylline,
have been administered in horses. Because they are both allergic diseases, eliminating the
inciting allergens is crucial for effective response to therapy [420]. If disease occurs in a
stabled, indoor environment, as is typical with RAO-affected horses, it is best to move
the horse to the pasture [451]. If disease occurs in the pasture, as is typical with pasture
heaves horses, it is important to move the horse indoors. Problematic for pasture heaves
horses is the fact that indoor housing does not fully mitigate their exposure to pasture
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aeroallergens. Efforts should be made to reduce the amount of dust in the environment as
well, by wetting hay, or switching to a pelleted diet, and by changing the bedding to
wood chips or pelleted paper [488, 489]. Exercise should be kept to a minimum during
disease exacerbation. Controlling clinical signs, airway inflammation, and airway
hyperreactivity are important therapeutic goals [416].
Importance as a model of asthma
RAO and pasture heaves share a common clinical presentation and
immunological similarities to severe human asthma. Like asthmatics, horses have all four
cardinal facets of asthma, including airway hyperresponsiveness, reversible airway
obstruction, airway inflammation, and airway remodeling [396, 399-402]. Further, like
human asthmatics, affected horses have airway remodeling that includes goblet cell
metaplasia and hyperplasia, smooth muscle proliferation, airway fibrosis, and mucus
hypersecretion [120, 399, 404, 405]. Horses are also a genetically outbred population,
akin to humans, and treatment and response are similar in humans and asthmatics [401].
However, one facet of asthma is particularly unique to horses relative to animal asthma
models. In horses with RAO/pasture heaves, the disease is chronic and progressive,
recurring regularly with re-exposure to inciting allergens despite periods in which the
horse is removed from the allergen. This facet of disease, reflects persistent sensitivity to
the inciting allergens and is a critical feature of asthma that is not found in induced
animal asthma models such as rodents that lose antigen responsiveness following
withdrawal of the sensitizing antigen [302]. Clinical similarities between asthma and
RAO/pasture heaves, association of airway neutrophilic inflammation with more severe
forms of asthma [266], together with the absence of airway neutrophilic inflammation,
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airway remodeling, and persistent sensitivity to antigen in rodent asthma models [283,
290, 294] highlight the value of RAO/pasture heaves as a research model of neutrophilic
asthma. Accordingly, horses with RAO/pasture heaves present a powerful model for
investigating the pathophysiologic mechanisms contributing the neutrophilic asthma and
for directing future therapeutic discovery.
Systems biology
"Systems biology is about putting together rather than taking apart, integration
rather than reduction. It requires that we develop ways of thinking about integration that
are as rigorous as our reductionist programmes, but different. ... It means changing our
philosophy, in the full sense of the term." - Denis Noble [490]
Systems biology is an attempt to structure knowledge into hierarchical levels,
from gene products to whole organisms, and to determine rules that will allow navigation
between levels [491], aiming for a system-level understanding of biological systems.
Understanding a biological system at a systems-level involves embracing the network of
dependent yet interconnected components that comprise a unified, complex organism, as
opposed to focusing on the characteristics of isolated parts of a cell or organism [492].
This is a relatively new way to approach molecular biology and genetics, but the
approach has been used in other branches of science, including physics, engineering,
economics, sociology, psychology, and ecology [492, 493]. Although the definition
varies throughout the literature, it is generally accepted that systems biology is
interdisciplinary, making use of the principles, knowledge, and tools of biology,
computer science, physics, chemistry, engineering, medicine, and genetics, bridging the
gaps between disciplines [494].
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History
The conceptual basis of systems biology dates back to the 17th century, when
reductionism and mechanistic thinking were initially developed. The reductionist
approach was developed by René Descartes and is based on the idea that complex
situations can be reduced into manageable pieces that can then each be investigated and
reassembled into a whole [492]. Mechanistic biology also developed during the 17th
century, with the idea that natural systems were considered to be merely mechanisms
with a more or less complex machinery [494]. These two philosophies led to great
discoveries in mathematics and physics, sanctioning the mechanistic thinking and
reductionist method as the way to develop a successful scientific approach [492, 494].
Mechanistic biology reached its peak in the early 1900s, when Jacob Loeb wrote that
organisms were nothing but complex machines, with mechanisms that must be rigid and
invariant [495]. This concept was objected by scientists for two reasons: Aristotelian
views, or "the whole is something over and above its parts and not just the sum of them
all" [496] and the introduction of "holistic biology" by Jan Smuts, according to which the
comprehension of systems as a whole is irreducible [497], meaning "the properties of
systems could not be reduced to those of their constituent parts [494]." Although
mechanistic reasoning is no longer a prominent biologic methodology, reductionist
approaches remain in use [494]. Contemporary biology successfully applied reductionist
methods to investigate up to the last molecular bases of biological phenomena [494], but
new technologies were needed to define and understand the behavior of systems. The
enormous development of fields including molecular biology, genetics, biochemistry, and
computer science during the 1900s made possible the scientific and technological
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revolution of the 1980s-2000s, with the introduction of the new field of systems biology
at the beginning of the 21st century [498, 499]. Table 2.1 highlights some significant
events and landmarks leading up to the advent of systems biology.
Prior to 1944, it was believed that proteins were responsible for hereditary
characteristics, but Avery et al., through experiments with D. pneumoniae, discovered
that DNA was linked to heredity [500]. Just a few years later, discovery that DNA had a
double-helical structure, allowed scientists to begin to understand the basic mechanisms
of DNA replication, protein synthesis, gene expression, and the exchange and
recombination of genetic material [501]. The development of recombinant DNA
techniques laid the foundation for a new area of scientific research [504], including the
identification, mapping, and sequencing of genes. DNA sequencing evolved from the first
methods for DNA sequencing, which included chemical sequencing and the more
economical Sanger-sequencing [506, 507], to semi-automatic sequencing technologies, to
the release of the first automated DNA sequencing machine in 1986 [508]. Sanger
sequencing, or shot-gun sequencing, was the predominant form of sequencing for a
quarter of a century, until its replacement with next-generation sequencing technologies
(NGS) in 2005 [513]. In the late 80s, discussion on creating the Human Genome Project
began in earnest, with a meeting from the United States Department of Energy. The
launch and implementation of the Human Genome Project promoted new technological
improvements, including -omics technologies and computational tools, contributing to the
rapid development of modern systems biology [494, 514, 515].
Since its beginning in the 1990s, systems biology has seen rapid development.
This development is largely due to a combination of three things: the reinforced holistic
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approach to biology, the differentiation of life into biological domains, and the
advancement of technology, including the internet, to accelerate accessibility of
bioinformatics. In 1999, Hartwell et al. indicated that functional modules should be
recognized as critical levels of biological organization, and general design principles rule
the structure and function of said modules [511]. This use of modular organization and
design principles became a new approach to study biological systems, influencing further
development of systems biology.
The first genome, Haemophilus influenzae, was sequenced in 1995 [510]. Shortly
afterwards, the human genome was sequenced (2001) [512], and since then, the number
of sequenced genomes has increased exponentially, as technologies improve and costs
decrease. For instance, in 2012, 282 permanent drafts of genomes existed in the Genomes
OnLine Database (GOLD) [516], and in 2013, an additional 968 more genomes were
completed with 4914 permanent drafts. In 2014, there were 2031 additional completed
genomes, and 15,653 permanent drafts [517]. Access to these data, along with increases
in computational power, technology, and bioinformatics tools, has allowed researchers to
describe gene and protein functions and interactions, leading to improvements in clinical
diagnostics, understanding of disease risk, therapeutic identification, prenatal testing,
discovering disease-related genes, synthetic biology, understanding of viruses and
bacteria, and many others [518].
The systems biology approach to asthma
-Omics begins with the collection and processing of large volumes of highthroughput data and the subsequent computational and statistical analysis of thousands of
proteins, mRNAs, miRNAs, transcripts, etc [519]. With asthma the -omics approach has
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already been used to identify asthma-associated genes and proteins based on expression
values, highlight asthma-related signaling networks, potential biomarkers of disease,
evaluate therapeutics, and further describe molecular mechanisms of asthma endotypes
[520-524]. Applying unbiased -omics methods, coupled with a hypothesis-driven project,
is ideal for discovery of new disease pathways and processes. There is no one standard
for the application of systems biology, so the strategies used vary depending on the type
and amount of data available and the questions to be asked [519].
Genome-wide association studies (GWAS) examine associations between
genotype and phenotype, resulting in the unbiased identification of genetic loci. Many
GWAS of asthma have been conducted, and the 17q21 locus is frequently associated with
disease risk [163, 525, 526]. Transcriptomics, or the systematic, unbiased, quantitative
and qualitative characterization of RNA transcripts across the genome, has transformed
our understanding of cellular function [527]. Microarrays first made the analysis of the
transcriptome possible. Using microarrays it is possible to detect variations in expression
of any gene included within the predefined probes on the array chip [528]. The main
advantage of microarrays over next generation sequencing methods is the comparatively
low running cost [529]. Today most researchers use direct high-throughput next
generation sequencing (RNA sequencing) which has become increasingly more cost
effective. RNA sequencing (RNA-seq) offers distinct advantages over microarrays,
particularly that it covers the whole transcriptome without bias, allowing researchers to
identify novel transcripts [530]. Proteomics encompasses the systematic analysis of
protein populations through identification, quantification, and analysis [531]. The
predominant method used to investigate respiratory diseases is expression proteomics
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through either 2DE or LC-MS analysis [532]. In 2DE, proteins are separated in
isoelectric focusing strips according to their net charge, and then are separated by
molecular mass through polyacrylamide gel electrophoresis (PAGE) [533]. The ideal
protein identification method is through MS-peptide mass fingerprinting along with
sequencing of selected peptides using tandem mass spectrometry (MS/MS) [532]. LCMS allows any two samples to be qualitatively and quantitatively compared, providing
information about differentially expressed genes, and although 2D PAGE is still
commonly used, LC-MS is used for a majority of research work in the respiratory field
[532]. Although much can be gained from transcriptomics or proteomics alone, the most
valuable information is likely to be from a combination of transcriptomics as a measure
of gene regulation, and proteomics as a measure of post-translational information [534].
Although metabolomic studies have also been used to investigate asthma, a majority of
the scientific literature is centered around proteomic and transcriptomic discoveries.
Systems biology-based research investigations into equine RAO and pasture heaves are
just beginning.
Transcriptomics
Most transcriptome profiling to date has been performed with oligonucleotide
microarrays [535]. Within asthma, most array-based studies have involved relatively
small sample sizes (reviewed in [536]), but have still provided valuable information.
Woodruff et al. (2007) used gene expression microarrays to identify and compare gene
expression from airway epithelial cells from asthmatic patients, healthy patients, and
smokers [537]. Within the same study, they found that IL-13 lead to the upregulation of
chloride channel, calcium-activated, family member 1 (CLCA1), periostin, and serine
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peptidase inhibitor, clade B (ovalbumin), member 2 (serpin B2) in asthmatics but not
smokers. After corticosteroid treatment, all three genes were downregulated, but FK506binding protein 51 became upregulated; a gene that was found to be inversely correlated
to poor response to corticosteroids [537]. In a study on childhood wheezers (Kapitein et
al., 2008), gene expression microarrays were used to examine CD4+ T cells from blood
samples collected from transient wheezers, persistent wheezers (considered asthmatics),
and healthy controls. Both affected groups had increased expression of several genes with
documented effects on airway hyperresponsiveness and allergic responses. For example,
a) complement component 5 receptor 1 (C5R1), b) a gene that produces interleukin-12
through macrophages and monocytes, driving type-1 adaptive immune responses [538]
and c) heat shock protein A1A, which has been shown to correlate to increasing severity
of asthma and neutrophil count in both sputum and plasma [539]. In 2013, Fu et al.
performed gene expression microarray analysis on asthmatics with and without systemic
inflammation, a characteristic that has been associated with neutrophilic airway
inflammation in asthma [540]. Those with systemic inflammation showed evidence of
increased serum levels of C-reactive protein and IL-6. 449 genes were identified that
were significantly altered in sputum between the two groups. These genes were involved
with IL-1, TNF-α, NF-Κß, and Kit receptor pathways, and were related to the presence
and severity of neutrophilic inflammation [540].
Currently, most researchers are using RNA-sequencing technology over
microarrays to investigate asthma. A comparison of RNA-seq profiles of endobronchial
specimens from subjects with atopic asthma and healthy controls revealing 46
differentially expressed genes (DEGs) [520]. This same study conducted pathways
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analysis of the 46 DEGs, revealing networks associated with cellular movement, cell
death, and cellular morphology. Within their DEGs, only a few had previously been
associated with asthma, including SLC26A4 (pendrin) , periostin, chloride channel
regulator 1 (CLCA1), and serpin peptidase inhibitor, clade B, member 2 (SERPINB2)
[520]. A recent study examining RNA-seq profiles of nasal brushings from asthmatics
and controls showed that airway nasal gene expression profiles can identify subjects with
asthma that is driven by IL33 [541]. In 2011, Baines et al. investigated asthma
phenotypes using gene expression profiling of induced sputum with hierarchical
clustering of the expression profiles [542]. Within their experiment, they were able to
describe three distinct phenotypes: 1) chronic airflow obstruction and poorly controlled
asthma, with increased exhaled nitric oxide, sputum eosinophilia, and decreased lung
function 2) severe airflow obstruction, higher sputum neutrophils, and decreased lung
function 3) higher sputum macrophages and lower eosinophils and neutrophils with
normal lung function. In the same study, they described overexpression of IL-1, TNF,
and NF-Κß, which correlated to increasing severity of clinical signs and neutrophilic
inflammation [542].
Potential mechanisms underlying glucocorticoid treatment in asthma have been
examined using RNA-seq. One study included endobronchial biopsy samples from
patients before and after prednisolone or placebo treatment. In this study, treatment with
prednisolone resulted in 15 differentially expressed genes, with two genes also associated
with airway hyperresponsiveness (FAM129A and SYNPO2) [543]. In a separate study,
the effect of dexamethasone on airway smooth muscle responses was investigated,
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revealing 316 glucocorticoid-responsive DEGs including DUSP1, KLF15, PER1,
TSC22D3, C7, CCDC69, and CRISPLD2 [544].
MicroRNAs (miRNAs) are single-stranded RNA species that constitute a class of
noncoding RNAs emerging as key regulators of gene expression [545]. Aberrant
expression of miRNAs has been associated with pathogenesis of diseases including heart
disease, congenital organ defects, neurodegenerative diseases, and are being used to
investigate pulmonary diseases including asthma (reviewed in [545]).
In 2012, Jardim et al. analyzed human bronchial epithelial cells from mild
asthmatics and healthy controls using a microRNA (miRNA) microarray [522]. Of 66
total differentially expressed miRNAs, three, miR-let7f, miR-487b, and miR-181c were
significantly higher in asthmatic patients. miR-203 was significantly underexpressed in
asthmatics, and through network analysis, AQP4, a potential gene inhibited by miR-203,
was identified. After confirmation of results via RT-PCR, Jardim et al. demonstrated an
inverse relationship between miR-203 and AQP4, where asthmatics had decreased miR203 correlating to increased expression of AQP4 [522]. These results contrast those of an
earlier study conducted by Williams et al. (2009), where no differences between miRNA
profiles of airway biopsies from mild asthmatics and healthy controls were detected
[546]. However, a later study conducted in 2012 by Solberg et al., used miRNA
microarrays to analyze bronchial epithelial brushings from steroid naive asthmatics,
steroid-using asthmatics, and healthy controls, finding a completely different subset of
differentially expressed miRNAs [547]. This study also examined the effects of exposure
of IL-13 and subsequent administration of corticosteroids on miRNA expression. IL-13
caused repression of miR-34/449 family members, miRNAs with established roles in
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airway epithelial cell differentiation, but corticosteroids did not improve the repression
[547]. A 2013 study investigating alterations in bronchoalveolar lavage fluid (BALF)
exosomal miRNA profiles in healthy subjects and asthmatics before and after exposure to
an environmental challenge showed substantial differences in miRNA profiles between
groups, but not following environmental challenge [548].
Proteomics
Most proteomic approaches to human asthma are performed using sputum
samples, but some have been performed on lung biopsy samples, BALF, and plasma.
Recent examples of each are described here. In 2005, Wu et al. analyzed BAL fluid after
segmental allergen challenge using SDS-PAGE, followed by LC-MS/MS, resulting in the
identification of 160 differentially expressed proteins (DEPs) [549]. One protein, MMP9, was validated as a potential biomarker of disease. Cederfur et al. (2012) applied
galectin affinity chromatography to analyze BALF, identifying 175 DEPs, including
PIGR, SP-B, and SP-A2, and many galectin-binding glycoproteins [550]. O'Neil et al.
(2011) investigated the proteome of bronchial biopsies taken from asthmatics [523].
Compared to the proteome of healthy controls, the asthma bronchial proteome
demonstrated upregulation of several cytokines including SCGB1A1 and TNFSF13B; the
latter is associated with both TH1 and TH2 inflammation [551, 552]. Other known
asthma-relevant proteins that were upregulated in the asthmatic proteome relative to
controls included SERPINA1, thrombins, fibrinogens, and LMNA [523]. Singh et al.
(2012) analyzed plasma samples from asthmatics exposed to allergen challenge to
identify potential markers specific to the early or late asthmatic phase, but no specific
markers could distinguish the two responses [553]. Using a shotgun proteomics approach,
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Gharib et al. (2011) analyzed sputum from healthy subjects and asthmatic patients,
including five with exercise-induced bronchoconstriction [554]. Ten proteins were
significantly differentially expressed in asthmatic patients, including SERPINA1 (α1antitrypsin), a protein with a role in promotion of airway remodeling [555]. Within the
exercise-induced patient group, complement component 3 (C3) was significantly
upregulated [554]. C3 has many documented roles in asthma pathogenesis, including
airway mucus secretion, smooth muscle contraction, vascular permeability, release of
allergic mediators, and airway hyperresponsiveness [556, 557].
Proteomic profiles of neutrophilic asthma have also been investigated. In 2013,
Lee et al. conducted a study on patients with controlled and uncontrolled neutrophilic
asthma. Among 14 DEPs, S100A9 was identified as a specific marker for neutrophilic
uncontrolled asthma [558]. Proteomic analysis has also been performed on CD4+ T
lymphocytes from the blood of patients with uncontrolled asthma, revealing 14 DEPs,
including vimentin [559]. Brasier et al. (2008) established IP-10, IL-7 and GM-CSF were
different between high and low neutrophil asthmatics [560].
Metabolomics
Exhaled breath contains a complex gas mixture of volatile organic compounds
(VOCs) and nonvolatile compounds derived from exhaled breath condensate (EBC)
[561]. Samples are typically analyzed using metabolomic approaches based on mass
spectrometry [562]. Both components of exhaled breath have been investigated in regards
to asthma. Dallinga et al. (2010) examined breath samples analyzed for VOC by
chromatography-mass spectrometry. They were able to use VOCs to distinguish between
asthmatics and healthy controls [563]. Carraro et al. (2013) applied the metabolomic
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approach to EBCs from children with severe or nonsevere asthma, successfully
distinguishing between the two groups [564].
The systems approach to equine disease
One of the first attempts at mapping the genetic loci involved in RAO was carried
out in 2009 by Swinburne et al. [565]. Using a genome-wide scanning approach, they
located the chromosome regions responsible for inheritance in two half-sibling families
of Warmblood sport horses. Those two chromosome regions were ECA13 and ECA15,
with one family associated with ECA13, and the other family associated with ECA15.
Located within those regions were several candidate genes, including interleukin 4
receptor (IL-4R), IL-21R, chemokine (C-C motif) ligand 24 (CCL24), IL-27,
prostaglandin E receptor 4 (PTGER4), phosphodiesterase 4D (PDE4D), suppressor of
cytokine signaling 5 (SOCS5), and IL-17R [565].
The candidate genes for RAO identified by Swinburne et al. have been further
investigated by comparison to proteomics data generated from bronchoalveolar lavage
fluid (BALF) collected from RAO-affected and unaffected herd mates [566]. Of the eight
candidate genes investigated, those that had the greatest number of direct documented
molecular actions with the BALF proteins were SOCS5, IL-7R, PTGER4, and PDE4D.
IL-4R, IL-21R, and CCL24 had a large number of indirect interactions with the proteins
present in BALF of RAO-affected horses. In addition, Racine et al. found that many
proteins from the BALF in the IL-4R pathway interacted with the TNF-α family [566].
To this author's knowledge, this study reflects the one and only attempt to conduct a
proteomic analysis of BALF from RAO-affected horses.
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Similarly, only one gene expression analysis has been conducted on RAOaffected horses [567]. Lavoie et al. (2012) obtained peripheral lung biopsies via
thoracoscopy in both control and affected horses during disease exacerbation and
remission, and using suppression subtractive hybridization (SSH), only cDNAs that were
unique to clinical exacerbation of RAO were sequenced. 195 genes were identified,
including many that were associated with airway inflammation and remodeling. This
same study suggested targeting RhoA, PPP3CB, EDN1, and IGF1 signaling pathways as
potential targets for anti-remodeling therapies, particularly airway smooth muscle
hypertrophy, while focusing on LTB4 and PGD2 pathways as targets for antiinflammatory effects [567].
Summary
A growing understanding of asthma pathogenesis indicates that asthma is a
complex disease that is best classified as a syndrome comprised of different
pathophysiologic endotypes. Despite their differing pathophysiologic mechanisms,
endotypes share a similar clinical picture that includes reversible airway obstruction,
airway hyperresponsiveness, and chronic airway inflammation. [21]. Severe
noneosinophilic asthma (neutrophilic), is the most costly form of disease, and often
becomes refractory to treatment [87-89], creating a need for animal models to investigate
pathophysiologic mechanisms and therapies for this asthma endotype [401]. Of all the
animal models of asthma, the cat and the horse are the only two species with a naturally
occurring asthma-like disease [120]. The cat is an excellent model for allergic asthma,
due to its airway eosinophilia, while the horse is the optimal model for neutrophilic
asthma, as its airway inflammation is comprised mostly of neutrophils. Although the
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mouse model, and other animal models where disease is artificially induced have
provided some valuable information about asthma, many findings have not been
translated to understanding human disease or therapy [283].
There are two equine syndromes that are used to model human asthma: RAO and
pasture heaves. They are clinically similar spontaneous asthma-like disease of horses,
with RAO typically occurring in stabled horses in temperate climates [389], and pasture
heaves in pastured horses in hot, humid climates [393]. There are many similarities
between RAO/pasture heaves and asthma, although RAO has been described in more
detail. Significantly, RAO models the clinical hallmarks of asthma: chronic airway
inflammation, reversible airway obstruction, airway hyperresponsiveness, and airway
remodeling [39, 40].
Systems biology has rapidly developed over the past two decades. The sequencing
of the human genome led to increased availability to technology and created rapid
advancements in the need to derive biologically relevant information from genome scale
expression data including microarrays, proteomes and transcriptomes [512]. Since the
herald of systems biology, countless proteomic and transcriptomic profiles of the
asthmatic syndrome have been performed. Currently, most research is done via
proteomics and next-generation sequencing technologies. A handful of studies have been
performed on RAO; one on proteomics of BALF [566] and one where lung biopsy cDNA
was sequenced [567]. At this juncture in the literature, no studies using -omics
technologies have been performed on pasture heaves. The overarching goal of this
dissertation work is to identify evidence of shared molecular events relevant to asthmatic
airway neutrophilia in horses with pasture heaves. This has been accomplished through
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the following steps: 1) assign functions to equine gene products in a manner that is
computationally accessible, 2) identify conservation of gene functions in the lungs of
normal horses, mice and humans, and 3) identify molecular events contributing to airway
neutrophilic inflammation in pasture heaves lung lavage proteomes and their
conservation in human asthma. This work is the first to use -omics technologies to
investigate pasture heaves.
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Table 2.1

Significant historical discoveries preceding systems biology

Year(s) Event
Obtained conclusive evidence that DNA
1944
was the carrier of hereditary
characteristics, with Diplococcus
pneumoniae bacterium.
Double helical structure of DNA
1953
described.(Received 1962 Nobel Prize in
Physiology or Medicine.)
1960s- Progress made in the understanding of the
structure of genes, and mechanisms of
1980s
replication, expression, and regulation in
prokaryotes and viruses.
Simulations of integrated molecular
1963
functions performed on analog computers
The idea of recombinant DNA was first
1969
proposed.
First gene sequenced - Bacteriophage
1972
MS2, an RNA virus that infects E. coli
Chemical DNA sequencing developed;
1977
Maxam-Gilbert sequencing
Chain-termination method DNA
1977
sequencing developed; Sanger sequencing.
(Received 1980 Nobel Prize in
Chemistry.)
Polymerase chain reaction (PCR)
1983
invented. (Received 1993 Nobel Prize in
Chemistry.)
First automated DNA sequencer invented,
1987
using the Sanger-sequencing method.
High throughput, genome scale, data-rich
1990biology
2000
The first complete genome sequenced
1995
from a free-living organism, Haemophilus
influenzae.
Functional modules recognized as critical
1999
levels of biological organization;
influenced the development of systems
biology.
Human genome sequenced using Sanger2001
sequencing.
Systems biology first described in
2001
scientific literature.
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Investigators
Oswald T. Avery, Collin M.
MacLeod, Maclyn McCarty
[500]
James Watson, Francis Crick
[501]
Various [502];

Brian Goodwin [503]
Peter Lobban [504]
Walter Fiers [505]
Allan Maxam, Walter Gilbert
[506]
Frederick Sanger [507]

Kary Mullis [289]
Lloyd M. Smith [508]
Various [509]
Robert D. Fleischmann et al.
[510]
Leland H. Hartwell et al. [511]

Eric S. Lander et al. [512]
Trey Ideker et al. [498]
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Abstract
Background
The horse genome is sequenced, allowing equine researchers to use highthroughput functional genomics platforms such as microarrays; next-generation
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sequencing for gene expression and proteomics. However, for researchers to derive value
from these functional genomics datasets, they must be able to model this data in
biologically relevant ways; to do so requires that the equine genome be more fully
annotated. There are two interrelated types of genomic annotation: structural and
functional. Structural annotation is delineating and demarcating the genomic elements
(such as genes, promoters, and regulatory elements). Functional annotation is assigning
function to structural elements. The Gene Ontology (GO) is the de facto standard for
functional annotation, and is routinely used as a basis for modelling and hypothesis
testing, large functional genomics datasets.
Results
An Equine Whole Genome Oligonucleotide (EWGO) array with 21,351 elements
was developed at Texas A&M University. This 70-mer oligoarray was designed using the
approximately 7x assembled and annotated sequence of the equine genome to be one of
the most comprehensive arrays available for expressed equine sequences. To assist
researchers in determining the biological meaning of data derived from this array, we
have structurally annotated it by mapping the elements to multiple database accessions,
including UniProtKB, Entrez Gene, NRPD (Non-Redundant Protein Database) and
UniGene. We next provided GO functional annotations for the gene transcripts
represented on this array. Overall, we GO annotated 14,531 gene products (68.1% of the
gene products represented on the EWGO array) with 57,912 annotations. GAQ (GO
Annotation Quality) scores were calculated for this array both before and after we added
GO annotation. The additional annotations improved the meanGAQ score 16-fold. This
data is publicly available at AgBase (http://www.agbase.msstate.edu/).
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Conclusions
Providing additional information about the public databases which link to the
gene products represented on the array allows users more flexibility when using gene
expression modelling and hypothesis-testing computational tools. Moreover, since
different databases provide different types of information, users have access to multiple
data sources. In addition, our GO annotation underpins functional modelling for most
gene expression analysis tools and enables equine researchers to model large lists of
differentially expressed transcripts in biologically relevant ways.
Background
Although the availability of a completed horse genome sequence enables
researchers to use genomic technologies in their research [1], deriving value from high
throughout genomics datasets requires genomic annotation. Genomic annotation includes
the demarcation of functional elements within the genomic sequence (“structural
annotation”) and associating functional data with these same elements (“functional
annotation”). Structural annotation is initially provided during the final stages of genome
sequence assembly using computational pipelines to predict open reading frames and
other functional elements. For example, the National Center for Biotechnology
Information (NCBI) Gnomon annotation pipeline
(http://www.ncbi.nlm.nih.gov/genome/guide/gnomon.shtml) combines ab initio
predictions with sequence homology based upon RefSeq transcript alignments of the
known genes. This structural annotation pipeline currently identifies 21,842 horse genes,
and of these, 82.4% are “predicted” based upon sequence similarity with known genes
from other species (as of 10/04/08). This means that these 17,997 horse genes are only
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listed because they are similar in sequence to genes that are already known to exist in
other species.
In contrast to structural annotation, functional annotation is not generally done
automatically as part of the genome sequencing process. Typically, functional annotation
is done as a separate, focused effort and the de facto method for functional annotation in
eukaryote genomes is the Gene Ontology [2]. The GO is a structured network consisting
of defined terms and the relationships between them that describe three attributes of gene
products: Molecular Function, Biological Process and Cellular Component [3].
Annotation to the GO involves providing information about the gene product being
annotated, its attributed function and the evidence for associating the function with this
gene product [4]. There are two broad types of GO evidence codes: direct experimental
codes (the evidence codes used for biocuration of published literature) and indirect
evidence codes. Indirect evidence codes include function prediction based on sequence
such as “inferred from sequence orthology” (ISO), where functional conservation is
inferred for predicted orthologs, and “inferred from electronic annotation” (IEA), which
includes function predicted based on functional motifs and domains [5]. The European
Bioinformatics Institute GOA Project (EBI GOA) provides IEA based GO annotations
for all proteins in the UniProtKB database [5].
Analyzing microarray data using GO has provided new insights into agriculturally
important areas of research, including reproduction [6], lactation [7], adipogenesis [8]
and animal health [9, 10]. Moreover, GO annotation has become the accepted standard
for functional annotation and its use is growing exponentially in species that have a
history of dedicated GO annotation effort [2, 11]. GO annotations provided by GO
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Consortium members are used by public databases (eg. Entrez Gene, UniProt), genome
browsers (eg. Ensembl), commercial vendors (eg. Affymetrix, Ingenuity Pathways
Analysis) and freely available analysis tools (eg. Onto-Tools [12], Cytoscape [13]).
However, while there are many tools available for analyzing microarray data
(http://www.geneontology.org/GO.tools.shtml#micro), researchers wishing to do
functional analysis of their equine array results are hampered by the lack of GO for
equine gene products represented on microarrays. For example although there are, 21,842
horse genes, only 1,582 equine proteins are represented in the UniProtKB database, so
only 7.2% of horse gene products have any GO annotation. This is further complicated
since different tools use different database accessions, and it is currently difficult to
determine the equivalent database accessions for horse sequences found in different
public databases.
If equine researchers are to translate functional genomics results into practical
solutions for equine health and production, they need to be able to translate data provided
by high throughput functional genomics platforms (such as microarrays) into relevant
biological knowledge. The Texas A&M Equine Whole Genome-oligoarray is a 21,000
element 70-mer expression array designed from the assembled equine genome sequence
in order to represent the majority of expressed equine sequences.
Briefly, the vast majority (97.5%) of the genes were documented by one or more
transcript sequences (RNA, UniGene or EST) while the remaining (2.5%) were
documented solely by a protein hit. The oligo design process searched for 70-mer long
hybridization probes representing all genes with due consideration to probes reporting
multi-copy genes and other more complex cases. The probe selection process resulted in
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21,351 probes (20,461 addressing single-gene and 890 addressing multi-gene targets)
representing 22,296 genes. Appropriate positive, distance, specificity and negative
controls (total 321) were added. The probes were commercially synthesized (Invitrogen,
USA) and spotted onto UltraGAPS aminosilane coated slides with barcodes (Corning,
MA) using a Chip Writer Pro microarrayer (BioRad, CA) equipped with 24 Telechem
SMP3 pins (TeleChem International, CA) [14, 15].
The Equine Whole Genome array is presently being validated and will be
available to the equine research community worldwide. To assist equine researchers with
the functional modelling of data produced using this array, we provide information about
public database accessions and functional annotations for elements represented on this
array. The method of functional annotation that we use to provide GO annotation for this
array is a combination of manual biocuration with computational analysis. We are
continuing to add additional GO annotations based upon published literature and all GO
annotations will be made publicly available at AgBase (http://www.agbase.msstate.edu/).
Results and discussion
Array annotation is useful because it facilitates integrating and interpreting large
data sets that are produced when oligoarrays are used to evaluate complex biological
processes. By annotating the equine whole genome array, researchers can step from lists
of differentially regulated gene products to model-based clustering of gene expression
data that advances the understanding of a biologic process. Further, accurate modelling
requires up-to-date functional annotation, regardless of species, and is relevant to
physiology, health, and disease.
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The importance of integrating biological knowledge gleaned from gene
expression profiles has been eloquently demonstrated by Chen and Wang. Using breast
cancer microarrays, they demonstrated that prediction models constructed based on
information from gene sets (pathways) outperformed the prediction models based on
expression values of single genes, with improved prediction accuracy and interpretability
[16]. This approach has also been applied to investigate the molecular basis of bone
remodelling in osteoarthritis. The researchers conducted a microarray gene expression
profile of the bone. Through this profile, researchers identified altered expression of two
signalling pathways and target genes in osteoarthritic bone. Using an annotated array,
these researchers were able to include genes with known or predicted roles in osteoblast,
osteocyte, and osteoclast differentiation and function [17].
The Texas A&M Equine Whole Genome-oligoarray is a 21,351 element
expression array that is presently being validated and will be available to the equine
research community worldwide. To ensure that users are able to derive value from their
array results we have provided information about the public database accessions
represented on this array and provided GO annotations for these gene products.
Database accession mapping
So that users could access the information from multiple public databases, we
provided multiple database accessions corresponding to each element on the array. To do
this we used ArrayIDer [18], a tool that retrieves structural annotations for ESTs and
provides 13 different identifiers for access to several publicly available databases
(including UniProtKB, Ensembl, RefSeq, IPI and UniGene). An example of the
ArrayIDer output is shown (Supplemental File 1) and the complete results will be made
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publicly available both with the array and on the AgBase website
(http://www.agbase.msstate.edu/). Until this data is available online, users can contact
AgBase for this mapping table or to run ID mapping for datasets.
The presence or absence of these gene products in different databases (Figure 3.1)
also provides biological clues about these gene products. For example, we found 337
elements that map to UniProt or Genbank RefSeq accession numbers. These are the
equine gene products that were experimentally studied prior to gene sequencing and are
likely to have published functional information available. A further 12,343 elements map
to “XP” accessions from NCBI; these are proteins that are predicted based upon the
NCBI structural annotation pipeline. These predicted gene products will not yet have
experimental functional information available but they will have sequence homology to
experimentally validated genes other species. The relatively large proportion of predicted
gene products is typical of newly sequenced genomes such as horse. For example 84% of
equine genes in NCBI are predicted, compared to 57.3% of the gene products represented
on this array. Moreover there are 4,399 additional gene assemblies represented on this
array that are not available from NCBI.
We found 2,164 Expressed Sequence Tags (ESTs) that did not map to any of the
current equine genes. ESTs represent the transcriptionally expressed elements within a
genome and since these do not align with any predicted genes, these may represent
mRNAs that are unique to horse. Another feature of newly sequenced genomes is that
there are rapid revisions and changes to the publicly available gene products as structural
annotation proceeds. We found 2,108 elements mapping to NCBI database accessions
that have been removed due to updates in structural annotation of the equine genome.
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GO annotation results
Since the EBI GOA Project provides IEA annotation for UniProtKB proteins, we
found that 208 equine UniProtKB entries already had existing GO. This represents 61.4%
of the UniProtKB but only 1% of the elements on the array. To improve the amount of
GO annotation for horse gene products represented on this array we did our own GO
annotation for equine gene products. In total, we added 57,912 GO annotations for
14,531 gene products, representing 68.1% of the elements on the Equine Whole Genomeoligoarray. Using a similar approach, the Affymetrix chicken genome array was
reannotated, increasing the number of probes associated with GO annotation by 45% and
the quality of annotation by 14%. The large proportion of equine gene products
associated with GO is partially due the improved ability to recognize equine: mammal
orthologs (compared to chicken) and that 31.9% of these gene products were listed as
“No Data” (ND), indicating that there is presently no functional information for these
elements. This GO annotation is summarized into broad functional groups using the GOA
and whole proteome GOSlim and the GOSlimViewer tool [19] (Figure 3.2). The GO
annotation is divided into three groups: cellular component, molecular function, and
biological process. The GO is evenly represented as 38% of the annotations are biological
processes, 35% are molecular functions, and 27% are cellular components. Furthermore,
there is information about membranes, cells, binding, regulation of biological processes,
cell communication, cellular processes, and metabolic processes, along with much more.
Thus annotation allows investigators to rapidly translate and integrate the full
complement of array data into a bar code of structurally and functionally meaningful
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changes at the protein level, changes which reflect the differential regulation of the
experimental intervention.
Since UniProtKB and RefSeq accessions are likely to have literature that
delineates protein function, we provided GO annotations by manual curation of existing
literature. Since this process is necessarily time consuming this effort is continuing. To
provide initial GO annotation we used known orthologs to human, mouse and rat genes
that have existing GO. Orthologs were manually verified and GO annotation based on
direct, experimental evidence transferred to the equine proteins. Fifty gene products were
manually annotated using ISO annotation, producing 529 annotations. A further 43
cannot be annotated until confirmation of the existence or absence of any literature
available.
While there is no experimental literature for any of the equine predicted proteins,
many of these are likely to have orthologs amongst mammalian species. By transferring
GO annotations from orthologous genes products that have experimental based GO
annotation 48,887 annotations were added for 12,227 predicted proteins, representing
98.3% of all predicted proteins. The other elements on the array had no experimental
literature or ortholog information available. Instead we provided GO annotations based
upon functional motifs using an automated pipeline to assess functional motifs [20]. We
added 6,466 annotations for 4,154 gene products, representing 23.6% of all gene
products. Notably, 76.4% of the gene products were annotated as “no data.” These are
summarized in Table 3.1.
Currently there are no commercial equine arrays, so there is no GO associated
with any of the other equine arrays. However we do have information about the GO
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provided for commercial arrays in other livestock species. Notably, although Affymetrix
provides GO annotation with their array annotation files, re-annotation of GeneChip
Chicken Genome Array resulted in a 37% increase in the number of array elements with
GO annotations and a 14% increase in the GO annotation quality [21]. For the more
closely related pig, only 11% of gene products on the Affymetrix array have GO
annotation.
The GO annotations that we have provided will be made publicly available via the
AgBase database. Since GO annotations change as new data becomes available and new
GO terms are added, this information will be updated periodically. Providing GO
annotations for 68% of the elements on the equine array is a significant achievement and
work is continuing to provide more detailed GO annotations and make these publically
available. Array users are encouraged to contact AgBase (agbase@cse.msstate.edu) with
specific questions about this data or to request further GO annotation.
GAQ score results
To determine the overall quality of the GO annotations added to the array, we
evaluated the GO Annotation Quality Score[22] for gene products associated with this
array both before and after we added our GO annotations. Briefly, GAQ score
quantitatively measures GO quality, which includes breadth of GO annotation, the level
of detail of annotation (depth), and the type of evidence used to make the annotation.
GAQ Scores are calculated exactly as described previously [22] and the meanGAQ Score,
the average GAQ Score for the dataset reported (Figure 3.3). Our GO annotations
improved the meanGAQ score 16-fold for the array, from 1.6 for the pre-existing GO to
26.7 for the completed or additional GO. The meanGAQ score was also reported and as
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expected there was an increase for each of the three ontologies. Cellular component
increased 11-fold, from 0.4 to 4.5, biological process increased 16-fold, from 0.5 to 8.1,
and molecular function increased 18-fold, or from 0.7 to 13.2.
Conclusion
This work is an initial computational based survey to provide GO annotation for a
broad range of equine gene products. However detailed, species specific function can
only be derived from manual curation of experimental literature and necessarily requires
a focused biocuration effort which is currently lacking for horse. Nevertheless, this GO
annotation provides the overview required to facilitate functional modelling of equine
datasets based upon this array. Moreover, the GO annotations are made publicly available
and will assist all equine researchers wishing to use the GO to model their data.
Methods
Accession mapping
Accession mapping was done using the standalone version of ArrayIDer from
AgBase[18]. ArrayIDer accepts data from any microarray containing expressed sequence
tag (EST) identifiers compatible with the NCBI UniGene database. ArrayIDer generates a
list of gene and protein accessions from the latest databases (NCBI UniGene and the
International Protein Index) and retrieves identifiers that match the EST input list.
ArrayIDer will be activated for the horse dataset but until this is available online, users
may contact AgBase to retrieve the mapping table or to run accession mapping for their
own datasets. ArrayIDer is available from AgBase
(http://www.agbase.msstate.edu/arrayider.html).
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GO annotation
Our strategy for providing GO annotations for gene products represented on this
array is summarized in Figure 3.4. We initially used GORetriever [19] to determine
which UniProtKB or RefSeq accessions already had existing GO annotations. The
remaining UniProtKB and RefSeq accessions were manually GO annotated based upon
functional literature and mapped to orthologous mammalian gene products with
experimentally based GO. Orthologs were determined using Ensembl version 53 and only
1:1 orthologs from human, rat, or mouse were returned. This type of GO annotation was
assigned “inferred from sequence orthology” (ISO) GO evidence code, based upon
standard GO Consortium procedures [4].
The NCBI predicted proteins do not have direct experimental evidence, and are
unlikely to have any orthologs. These were first annotated by ISO annotation, or if there
was no 1:1 ortholog available, we used known functional motifs to provide GO
annotation. This is an automated process and is referred to as “inferred from electronic
annotation” (IEA). Other gene products represented on the array were also GO annotated
using the IEA method.
The results of these GO annotations were summarized using GOSlimViewer [19]
with the GOA and whole proteome GOSlim Set.
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Figure 3.1

Gene products represented on the equine whole genome array

Array gene products were linked to public databases to facilitate functional modelling.
1.6% of the elements represent experimentally validated products found in UniProtKB or
the RefSeq databases while 58.2% are predicted based upon computational structural
annotation of the horse genome. 20.6% are predicted genes not available from NCBI and
10.1% are ESTs that are not linked to known or predicted horse genes. A further 9.9%
have been removed from the NCBI databases due to structural reannotation.
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Functional grouping of equine array gene products using GOSlimViewer.

The GO annotation is divided into three broad functional groups using the GOA and whole proteome GOSlim and the GOSlimViewer tool: A. Biological Process, B. Molecular Function, and C. Cellular Component. Further
subcategories within functional groups A-C are listed on the y-axis and the frequency of this function within the array is represented on the x-axis. The functional group, “biological process” had the most GO IDs represented,
followed by “molecular function,” and finally “cellular component.” In A, the largest three subcategories were: cellular process, regulation of biological process, and metabolic process. In B, binding was the most annotated
function. For C, the top three cell component subcategories were e cell, cell membrane, and cellular component. Particularly significant is the wide display of GO IDs shown, suggesting the equine whole genome array is fairly
comprehensive.

Figure 3.2
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Figure 3.3

GO Annotation Quality (GAQ) score

GAQ Scores were calculated for the existing GO annotation on the array and the GO
annotation available after we added the additional annotations described in this paper.
GAQ Scores are calculated exactly as described previously [22]. Briefly, GAQ score
quantitatively measures GO quality, which includes breadth of GO annotation, the level
of detail of annotation (depth), and the type of evidence used to make the annotation.
Additional GO improved the meanGAQ score 16-fold, from 1.6 for the pre-existing GO
to 26.7 for the completed or additional GO. meanGAQ score for each ontology is shown
as well. Cellular component increased 11-fold, from 0.4 to 4.5, biological process
increased 16-fold, from 0.5 to 8.1, and molecular function increased 18-fold, or from 0.7
to 13.2.
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Figure 3.4

Flow chart demonstrating the functional annotation process

Functional annotation begins by accession mapping through ArrayIDer. ArrayIDer
divides the input file into broad categories: predicted gene products, ESTs, non-NCBI
predicted gene assemblies, and UniProtKB or Genbank RefSeq, as well as predicted
proteins that were removed from the database. Predicted gene products go down the ISO
pipeline, and the rest go through IEA pipelines, with the exception of UniProtKB or
RefSeq, which are sent to GORetriever. GORetriever pulls out the genes which already
have existing GO annotations, and the rest are manually curated by mapping orthologs to
human, mouse, and rat genes.

140

Table 3.1

GO Annotation of the equine whole genome oligoarray

Database Category

No. Gene Products

Number of GO
annotations added
2,559
48,887
4,546
1,920

UniProtKB/Genbank RefSeq 337
Predicted Gene Products
12,434
ESTs
2,164
Non-NCBI Predicted Gene
4,399
Assemblies
Predicted Proteins Removed 2,108
-from Database
21,351
57,912
TOTAL
A total of 57,912 annotations were derived from the Equine Whole Genome Oligoarray.
2,559 annotations were derived from the 337 UniProtKB and RefSeq accessions. 48,887
annotations were derived from 12,434 predicted gene products. 4,546 annotations were
derived from 2,164 ESTs. Finally, 2,108 predicted proteins removed from the database
were not annotated. Thus 21,351 gene products yielded 57,912 new annotations.
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Summary
The equine genome sequence enables the use of high-throughput genomic
technologies in equine research, but accurate identification of expressed gene products
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and interpreting their biological relevance requires additional structural and functional
genome annotation. Here, we employ the equine genome sequence to identify predicted
and known proteins using proteomics and model these proteins into biological pathways,
identifying 582 proteins in normal cell-free equine bronchoalveolar lavage fluid (BALF).
We improved structural and functional annotation by directly confirming the in vivo
expression of 558 (96%) proteins, which were computationally predicted previously, and
adding Gene Ontology (GO) annotations for 174 proteins, 108 of which lacked functional
annotation. Bronchoalveolar lavage is commonly used to investigate equine respiratory
disease, leading us to model the associated proteome and its biological functions.
Modelling of protein functions using Ingenuity Pathway Analysis identified carbohydrate
metabolism, cell-to-cell signalling, cellular function, inflammatory response, organ
morphology, lipid metabolism and cellular movement as key biological processes in
normal equine BALF. Comparative modelling of protein functions in normal cell-free
bronchoalveolar lavage proteomes from horse, human, and mouse, performed by
grouping GO terms sharing common ancestor terms, confirms conservation of functions
across species. Ninety-one of 92 human GO categories and 105 of 109 mouse GO
categories were conserved in the horse. Our approach confirms the utility of the equine
genome sequence to characterize protein networks without antibodies or mRNA
quantification, highlights the need for continued structural and functional annotation of
the equine genome and provides a framework for equine researchers to aid in the
annotation effort.
Keywords: Bronchoalveolar lavage, equine, genome annotation, proteomics
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Introduction
The completion of the equine genome sequence is a pivotal event for equine
researchers, as it enables the use of high-throughput whole genome technologies to
investigate clinically relevant hypotheses [1]. With the application of these technologies
to all species, including the horse, the major challenge facing researchers is now to
interpret the biological relevance of hundreds or even thousands of differentially
expressed genes that typify high-throughput data sets. The path to recognize the
biological relevance of a genome sequence begins with structural annotation, where
functional elements including open reading frames, genes, coding and non-coding
regions, and regulatory elements are demarcated. Refined structural annotation is a
fundamental requirement for accurately identifying gene products using high-throughput
functional genomics (microarrays, proteomics). Following this, biological functions are
assigned to the identified structural elements (functional annotation). For the horse, the
primary impediments to recognizing biological relevance from high-throughput data sets
are a lack of refinement in structural annotation of the equine genome and an absence of
robust functional annotation of the structural elements, particularly gene products.
The Gene Ontology (GO) is a species-unifying structured hierarchical vocabulary
for the annotation of biological knowledge relevant to gene products. Biological
functions of a gene product are identified by the European Bioinformatics Institute Gene
Ontology Annotation (EBI-GOA) Project [2] as 'cellular component,' 'molecular function'
or 'biological process' and are assigned GO terms with corresponding unique numerical
identifiers. The structured order of these ontologies, as well as their numerical identifiers,
makes GO amenable to computational analysis and able to be used to streamline
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identification of functions associated with gene products. As such, GO facilitates
modelling of large high-throughput functional genomic technology, turning data into
knowledge. The utility of the GO for modelling functional genomics data sets has made it
a de facto standard for gene product functional annotation [3]. Annotations from EBIGOA are accessible through the UniProt Knowledgebase (Uni-ProtKB) database [4]. In
addition, Ensembl [5], Entrez Gene [6] and Affymetrix [7] utilize these GO sources for
their functional annotation. However, the GO databases do not include annotations for
'predicted' gene products i.e. those without experimental evidence for their in vivo
expression. For example, of the nearly 20,000 protein coding genes predicted for horse,
only 1537 are represented in UniProtKB and can receive automatic GO annotation via the
EBI-GOA Project [2].
In the absence of experimental evidence for in vivo expression of a gene product,
other indirect lines of evidence are used to assign function, including electronic
annotation based upon functional motifs and sequences (inferred from electronic
annotation or IEA). The most rigorous of these is based upon the determination of
orthology relationships between species. Orthologous genes/proteins are those that exist
in multiple species that have diverged from a common ancestral gene that existed in the
last common ancestor [8-12]. Presuming the absence of evolutionary bottlenecks,
minimal evolutionary separation between orthologous pairs results in significant
structural similarity, increasing the likelihood of conserved function. Commonly
employed algorithms for assigning orthology include Homologene [13], Ensembl [5],
Inparanoid [8] and Treefam [14]. Differences between these algorithms are responsible
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for variations in the composition of an orthologous group between algorithms.
Furthermore, these are only predictions and should be validated experimentally.
The most rigorous annotation of protein function requires time consuming manual
biocuration of published literature. This is why, even in species such as human and
mouse, where the greatest efforts in GO annotation have been expended, manual curation
of literature to the GO lags behind the understanding of gene product functions
represented in contemporaneous peer-reviewed literature. Accordingly, most newly
sequenced genomes without funded GO biocuration, such as the horse, lack even
preliminary functional annotation. For the horse, this problem is compounded because the
breadth and depth of peer-reviewed literature provide limited experimental evidence for
in vivo existence of equine gene products. To begin to address this problem, we have
previously improved the breadth of available equine GO annotation by focusing on gene
products represented on the TAMU equine whole genome oligoarray and by providing
primarily computationally derived GO annotations for these gene products [15]. This
includes both predicted and known gene products accessible at AgBase [16]
(http://www.agbase.msstate.edu), our curated, open-source, web-accessible resource for
functional analysis of agricultural plant and animal gene products.
In addition to being a repository for GO annotations in nontraditional species,
AgBase provides tools to deliver GO annotations for large numbers of gene products.
Two such tools, GORetriever and GOanna [16], accept nucleotide or amino acid
sequences or accessions in various formats and return the associated GO annotations.
This is an essential first step in modelling large high-throughput equine data sets
(transcriptomes or proteomes) to identify their functional significance. Complementary to
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the information obtained from GO annotations are tools that model the gene products of
high-throughput data sets within the context of the complex interactions that characterize
biological systems. Examples of these tools, which facilitate identification of
relationships among genes, proteins, cell processes and diseases, include Ingenuity
Pathways Analysis (IPA) software (Ingenuity Systems®, http://www.ingenuity.com) and
Pathways Studio (Pathways Studio®,
http://www.ariadnegenomics.com/products/pathway-studio).
Nuances in both structural and functional annotation of the equine genome
influence the information obtained from high-throughput functional genomic
technologies, and tools that bridge these gaps are critical to realizing clinically applicable
discoveries. Our interest in equine respiratory disease, coupled with the central
dependence of equine athletic performance on respiratory function, were the stimuli for
our desire to understand the physiology represented by proteins in the fluid secretions of
normal equine lung. We used cell-free bronchoalveolar lavage fluid (BALF) from the
lungs of normal horses, followed by quantitative shotgun proteomics and computational
biology to provide experimental evidence for the expression of both known and predicted
proteins from the equine genome sequence. Knowledge of the biological functions of
these proteins was improved by assigning standardized nomenclature and GO annotations
based on orthology. Finally, the biological information associated with these proteins was
modelled using Ingenuity Pathways Analysis (IPA, Version 8.5; Ingenuity Systems) and
compared to normal cell-free human and mouse BALF proteins using GO Modelling
[16].
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Methods and materials
Cell-free bronchoalveolar lavage fluid samples
Bronchoalveolar lavage fluid was collected from six clinically normal horses as
previously described [17], placed immediately on ice, transported to the laboratory and
centrifuged (600 g 10 min 4 °C). Aliquots of cell-free BALF supernatant were frozen at 80 °C for subsequent proteomic analysis.
Protein isolation, digestion, and peptide detection
The workflow for sample analysis and modelling is summarized in Fig 4.1.
Detailed methods are provided as Supplemental File 2. Proteomic analysis was performed
twice using a composite sample consisting of 100 µg of BALF protein from each of three
horses. Triplicate aliquots of the composite (75 µg of protein each) were subjected to acid
precipitation and trypsin digestion and analysed using liquid chromatography tandem
mass spectrometry as previously described [18]. However, we did not perform
differential detergent fractionation, and we used one dimensional liquid chromatography
(1D LC) nanospray ionization and not electrospray ionization. 1D LC peptide separation
was achieved using a Thermo Surveyor MS pump and 5–50% acetonitrile (ACN)
gradient over 180 min followed by 95% ACN wash and 5% ACN equilibration with
0.1% formic acid as a proton source. Nanospray ionization of peptides was performed
using a Thermo Finnigan nanospray type I source operated at 1.9 kV with 8-µm internal
diameter silica tips at 500 nl/minute. Peptides were identified using a Thermo LCQ
DECA XP Plus ion trap mass spectrometer for 225 min per sample. Precursor mass scans
were performed using repetitive MS scans followed by three MS/MS scans of the three
most intense MS peaks. Dynamic exclusion was enabled with a duration of 2 min and a
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repeat count of two. Spectra were measured with an overall mass/charge (m/z) ratio range
of 300–1700.
Protein identification
Proteins were identified in the manner previously described [19]. Briefly, mass
spectra and tandem mass spectra were searched using TurboSEQUEST™ (Bioworks
Browser 3.3; ThermoElectron, Florida, USA) against an in silico trypsin-digested
database of equine non-redundant RefSeq proteins and filtered using a decoy searchbased probabilistic method in which only peptides with a probability ≤0.05 were
considered to be correct. The equine non-redundant protein database, which was
downloaded from the National Center for Biotechnology Institute on 30 October 2009,
contained 17,757 proteins and 1,347,511 unique peptides. Protein identifications and their
associated MS/MS data have been submitted to the PRoteomics IDEntifications database
(PRIDE; accessions 13712–13717) [20].
Functional analysis
To determine the biological relevance of proteins in the BALF, we performed
functional modelling of the proteins using GO analysis and also used Ingenuity Pathways
software to identify the biological functions that were significantly represented in the
BALF proteome. Briefly, we used GORetriever [16] to retrieve associated GO
annotations, and proteins that initially had no GO were annotated first based upon
orthology to annotated mammalian genomes (GO evidence code: ISO, or inferred from
sequence orthology) and second by sequence analysis to detect functional domains and
motifs (GO evidence code: IEA, or inferred from electronic annotation). Orthology to
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GO-annotated human, mouse and rat proteins was determined using Ensembl orthology
predictions, and analysis of functional domains was carried out using InterProScan; both
of these methods are routinely used by the AgBase database to provide first-pass GO
annotations for gene products.
Existing and newly assigned GO annotations were combined to provide a
comprehensive GO annotation set for our identified proteins. These data were
summarized using GOSlimViewer [16] with the generic slim set, which groups the
retrieved functional annotation information for the protein data set using common
ancestor GO terms in each of the three gene ontologies (cellular component, molecular
function and biological process). The resulting analysis summarizes the known biological
information for the healthy cell-free equine BALF proteome. We also compared the
biological information from our normal cell-free horse BALF proteome to that of human
[21] and mouse [22] cell-free BALF proteomes by retrieving the associated GO
annotations for the published human and mouse proteomes and modelling them in an
identical fashion using GOSlimViewer. To determine how the biological information in
the normal equine BALF proteome compares to biological information for all horse gene
products, we also obtained the complete GO annotation file for horse from AgBase and
summarized it using GOSlimViewer for comparison.
Finally, the normal cell-free BALF proteome was also modelled using Ingenuity
Pathways Analysis software (IPA, Version 8.5; Ingenuity Systems) to identify
significantly represented biological functions, pathways, and diseases, based on canonical
networks generated from rat, mouse and human data. Because IPA accepts only mouse,
rat, canine and human orthologs for upload and analysis, the human, mouse and rat
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orthologs were identified for each equine protein using Ensembl BioMart (Version 0.7,
Ensembl 56 set) [23] and uploaded to IPA. IPA selects 'focus genes' to be used for
generating biological networks. Focus genes are based on proteins from the input data set
that are mapped to corresponding gene objects in the Ingenuity Pathways Knowledgebase
(IPKB) and are known to interact with other genes based on published peer-reviewed
content in the IPKB. Based on these interactions, IPA builds networks with a size of no
more than 35 genes or proteins. A p-value for each network and canonical pathway is
calculated according to the fit of the user's set of significant genes/proteins. IPA
computes a score for each network from this p-value that indicates the likelihood of the
focus genes in a network being found together by chance. We selected networks scoring
≥2, which have >99% confidence of not being generated by chance [24, 25]. IPA assigns
biological functions to these networks using annotations from the scientific literature that
are stored in the IPKB, and a Fisher's exact test is used to calculate a p-value associated
with the probability that each biological function/disease or pathway is assigned by
chance. We used P ≤ 0.05 to select significant biological functions and pathways
represented in our proteomic data sets [24].
Results and discussion
Protein identification
We identified 582 unique proteins from the cell-free BALF of normal horses. A
list of identified proteins is accessible in Supplemental File 3, and the spectra for
identification of these peptides have been submitted to the PRIDE database. During
manuscript preparation, 17,859 of the 18,448 (96.8%) in the NCBI Reference Sequence
(RefSeq) non-redundant protein database carried the 'XP' designation in their RefSeq
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number, which signifies that there is not yet experimental evidence of in vivo expression
for these proteins. Proteins with documented in vivo evidence carry the designation 'NP'
in their RefSeq number. Of the 582 proteins identified in our normal cell-free BALF
proteome, 24 (4%) carried the NP designation and 558 (95.9%) carried the XP
designation. This result is in line with the overall composition of NCBI equine proteins.
The XP proteins within this equine BAL proteome data set constitute 3% of the total
proteins (both XP and NP) predicted by the equine genome sequence (and 3.4% of
proteins with the predicted (XP) designation). Identification of proteins with an XP
designation in equine samples is important to the annotation effort of the equine genome
sequence, because it provides experimental evidence for the in vivo expression of these
proteins, improving both structural and functional annotation of the genome sequence.
The 558 experimentally validated proteins were given standard nomenclature based upon
recommendations for standardized nomenclature for human genes [26], and we are
making this data available on the NCBI database.
GO annotation of identified proteins
Our initial GO survey of the 582 BALF proteins indicated that 408 proteins (70%)
had 2229 existing GO annotations, the majority of which were provided by our previous
equine annotation effort [15]. The remaining 174 proteins were annotated as previously
described [15], and as outlined in the methods section, yielding 870 annotations.
Ortholog-derived GO annotations (GO evidence code 'ISO,' inferred by sequence
orthology) added GO annotations for 72 proteins (12.4%), and GO annotations for the
remaining 102 proteins (17.5%) are based on functional motif analysis (GO evidence
code 'IEA,' inferred by electronic annotation). Predicted proteins were annotated 'no data'
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(GO evidence code 'ND'), as these proteins are computationally predicted and thus do not
have published functional data available. While GO was returned for all BALF proteins,
this is somewhat misleading, because 346 (59%) of the BALF proteins had 'ND' evidence
codes in at least one of the three GO ontologies (cellular component, biological process,
molecular function), signifying that the protein has been annotated but lacks functional
information in that ontology. The absence of GO annotation may affect any or all of the
three ontologies, and in our protein set, 108 (19%) proteins lacked GO annotation in all
three ontologies. These results, summarized in Table 4.1, highlight the need for a focused
effort to provide functional annotation for the equine genome sequence.
GO modelling
GOSlimViewer [16] was used to model the biological information associated with
GO annotations for the healthy cell-free equine BALF proteome by mapping GO terms to
the Generic GOSlim sets within each of the three ontologies (Generic GOSlim Set, 2009;
Figs 4.2–4.4). The most common GO cellular component annotations were 'intracellular '
(12.6%), 'cell' (20.6%) and 'component unknown' (22.1%; i.e. GO terms determined to
have a cellular component but not further categorized). In the GO molecular function
ontology, 19% of the GO annotations mapped to 'binding' (GO:0005488). 'Protein
binding' and 'catalytic activity' were highly represented, at 12.5% and 8.4%, respectively.
Finally, the most represented GO biological processes were 'unknown' (24.2%),
'metabolic process' (13.3%) and 'regulation of biological processes' (9.2%). The finding
that approximately 46% of the GO annotations for our 582 protein normal BALF
proteome map to 'component unknown' and 'biological process unknown' further
underscores the current challenges facing researchers in interpreting how lists of
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differentially expressed equine gene products support or refute an experimental
hypothesis.
To compare the functions of proteins in normal BALF to what is known about
proteins in the equine genome, a reference GOSlim data set was created from the equine
gene association file, which represents all GO annotations previously assigned to the
horse. Comparisons of the reference and BALF GOSlim sets support our approach,
demonstrating that the percentages of proteins within the top five groups of each
ontology in the BALF proteome align to the top five groups of each ontology within the
horse genome association file (Figs. 4.5-4.7). Within the 'cellular component ' ontology,
we identified a higher percentage of 'component unknown' and 'cell' GO terms in the
whole genome than the BALF normal proteome data; this is expected, as our BALF
sample is a lung lining fluid and cells are removed during processing. A higher
percentage of intracellular GO terms was identified in the BAL proteome, which may
initially seem counterintuitive to the absence of cell terms. However, it may reflect the
nature of the granularity of GO terms where, for example, proteins derived from
ribosomes or bound to DNA are within the 'intracellular ' category and thus constitute a
major portion of BALF protein associated with normal cell turnover and lysis within the
airways. In the molecular function ontology, 'protein-binding' activity was overrepresented in the BALF proteome, and this enabled us to rapidly identify proteinbinding pathways of interest. Within the biological process ontology, the only differences
detected between the BALF proteome and genome were small decreases in GO functions
associated with 'metabolic process,' 'regulation of biologic process' and 'signal
transduction;' again this most likely reflects the absence of cells.
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Pathway analysis
As there are currently no tools that allow us to do direct analysis of horse
pathways and networks, we relied on identifying orthologs from human and mouse.
Using these two species, we identified orthologs for 494 of the 582 total proteins
(84.4%). We note that the exclusion of 88 proteins could prevent the identification of
biologically relevant pathways and metabolic processes that address a research
hypothesis (included in Supplemental File 3). These omissions further highlight the need
for organized annotation and gene nomenclature efforts on behalf of the equine genome.
Regardless, the top biological pathways identified in descending order were carbohydrate
metabolism, cell-to-cell signalling and interaction, cellular function and maintenance,
inflammatory response, organ morphology, lipid metabolism and cellular movement,
which are all homoeostatic pathways that would be expected in healthy lung samples.
The top 15 pathways identified in normal equine BALF are represented in Fig. 4.8.
Comparative analysis of BALF proteomes using GO modelling
To compare the distribution of biological functions of proteins in normal equine
BALF to those in normal human and mouse BALF, we modelled published normal cellfree BALF proteomes containing 167 proteins (human) [21] and 297 proteins (mouse)
[22] by mapping the associated GO terms to the Generic GOSlim sets within each of the
three ontologies (Generic GOSlim Set, 2009). The horse BALF proteome contained 91 of
92 GOSlim categories identified in the human BALF proteome, corresponding to 2718
horse and 2972 human GO annotations. One hundred and five of 109 GOSlim categories
identified in the mouse BALF proteome were identified in horse, corresponding to 2718
horse and 5287 mouse GO annotations. Human and mouse GOSlim categories that were
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not represented in the equine proteome contained only a single annotation and were
mitochondrial organization for human, and mitochondrial organization, cellular
recognition, epigenetic regulation, molecular function and vacuole for mouse.
Comparisons of the top ten GOSlim categories within each ontology indicate that horse
and human BALF proteomes share 9 cellular component categories (unknown, cell,
intracellular, cytoplasm, protein complex, organelle, extracellular, cytoskeleton, plasma
membrane), eight molecular function categories (binding, protein binding, catalytic
activity, nucleotide binding, hydrolase activity, receptor activity and binding, peptidase
activity, enzyme regulator activity) and five biological process categories (process
unknown, metabolic process, regulation of biological process, multicellular organismal
development, transport).
Despite the mouse BALF proteome having approximately twice the number of
annotations of the horse BALF proteome, comparisons of the top ten GOSlim categories
of horse and mouse BALF proteomes were in direct agreement with cellular component
categories, which included organelle categories in addition to the nine categories
previously detailed as common to human and horse. The eight molecular function GO
categories and five biological process GO categories that are conserved in horse and
human are identically conserved in mouse. Top GOSlim categories in the BALF
proteome of horse, human and mouse are summarized in Figs. 4.9-4.11. These
conservations in the distribution of biological functions of normal BALF proteome across
horse, human and mouse support not only the utility and validity of GO modelling of
functional genomic data, but also speak to the comparative utility of the horse as a model
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in respiratory investigations, particularly in light of the ease of attaining large volumes of
BALF from horses when compared to human and mouse.
Conclusion
Genomic technologies, coupled with the equine genome sequence, provide the
potential to identify thousands of differentially expressed genes that have not been
previously identified in the horse. We illustrate this by employing proteomics to identify
582 proteins in equine BALF, 558 of which were previously only computationally
predicted. However, the ability to identify the full complement of gene products coded
within the equine genome and to develop system models that allow researchers to
recognize changes within large functional genomics data sets that are clinically relevant
to equine disease necessitates a concerted effort towards both structural and functional
genome annotation. To identify clinically relevant biological functions represented in
normal equine BALF, a sample commonly used to diagnose and investigate inflammatory
lower airway disease, which affects 12% of performing horses [27], we modelled our
BALF proteome using both IPA and GO. These efforts highlighted challenges to system
modelling of equine samples that extend beyond rudimentary structural and functional
annotation, such as assignment of standard gene nomenclature, limited experimental
evidence for in vivo expression of equine gene products and temporal delay between
peer-reviewed literature and annotation to GO. Substantiating the validity of our BALF
proteome and modelling system, Ingenuity Pathways Analysis identified key
homoeostatic processes as predominating in the BALF proteome, including carbohydrate
metabolism, cell–cell signalling and interaction, and cell function and metabolism.
Furthermore, GO modelling of normal equine BALF proteome identified seven known
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cellular component GO categories (cell, intracellular, cytoplasm, protein complex,
organelle, extracellular, cytoskeleton, plasma membrane); eight molecular function
categories (binding, protein binding, catalytic activity, nucleotide binding, hydrolase
activity, receptor activity and binding, peptidase activity, enzyme regulator activity); and
four known biological process categories (metabolic process, regulation of biological
process, multicellular organismal development, transport) as conserved among the top 10
categories in each ontology between the normal BALF proteomes of human, mouse and
horse. Our presentation of the functional characterization of the BAL proteome using GO
and pathways analysis modelling is novel and important in equine research, because it
demonstrates a framework for approaching large functional genomic data sets to realize
biologically relevant information that addresses research hypotheses and enables
comparisons of results from disease models across species.
Using our BAL proteomics analysis, we have highlighted some impediments to
effectively employing the equine genome sequence and employing genomic technologies
to investigate clinical conditions of relevance to the equine industry. In addition, we
present the first BAL proteome and an initial characterization of this proteome using GO
modelling and IPA analysis.
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Figure 4.1

Strategy for identifying biological relevance of high-throughput data sets
from horses.

Proteins identified by mass spectrometry are mapped to existing orthologs using BioMart
and then analysed using Ingenuity Pathways Analysis (IPA). Proteins are also submitted
to GORetriever to identify existing Gene Ontology (GO) annotations. Proteins without
GO in GORetriever move through sequence orthology and electronic annotation to
identify GO. All GO annotations for the protein data set are categorized using
GOSlimViewer.
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Figure 4.2

Cellular components transferred to orthologous proteins in equine
bronchoalveolar lavage fluid.

The Gene Ontology (GO) annotations are summarized in broad terms of cellular
component. These GO annotations are publicly available on AgBase [16].
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Molecular functions transferred to orthologous proteins in equine bronchoalveolar lavage fluid.

The Gene Ontology (GO) annotations are summarized in broad terms of molecular function. These GO annotations are publicly
available via the AgBase database [16].

Figure 4.3
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Biological processes transferred to orthologous proteins in equine bronchoalveolar lavage fluid.

The Gene Ontology (GO) annotations are summarized in broad terms of biological process. These GO annotations are publicly available via the AgBase database [16].

Figure 4.4
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Figure 4.5

Top five Gene Ontology (GO) categories in normal bronchoalveolar lavage
fluid vs. all equine GO annotations for the cellular component gene
ontology.

Proteins are represented as a percentage of the total.
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Figure 4.6

Top five Gene Ontology (GO) categories in normal bronchoalveolar lavage
fluid vs. all equine GO annotations for the molecular function gene
ontology.

Proteins are represented as a percentage of the total.
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Figure 4.7

Top five Gene Ontology (GO) categories in normal bronchoalveolar lavage
fluid vs. all equine GO annotations for the biological process gene
ontology.

Proteins are represented as a percentage of the total.
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Figure 4.8
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Top 15 biological functions represented in the normal equine bronchoalveolar lavage fluid proteome.

Figure 4.9
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Top Gene Ontology categories in normal bronchoalveolar lavage fluid from horse, human and mouse for the cellular
component gene ontology.

Figure 4.10
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Top Gene Ontology categories in normal bronchoalveolar lavage fluid from horse, human and mouse for the
molecular function gene ontology.

Figure 4.11
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Top Gene Ontology categories in normal bronchoalveolar lavage fluid from horse, human and mouse for the
biological process gene ontology.

Table 4.1

Comparison of functional annotation of the horse genome and its impact on
the annotation of a normal bronchoalveolar lavage fluid (BALF) proteome.

(Non-redundant)
Proteins
Predicted Proteins (XP
RefSeq identifier)
Proteins with Gene
Ontology Annotation
Proteins with NO in at
least one ontology
Proteins with ND in all 3
ontologies

Horse genome
21,335 (18,848)

Normal BALF data set
582

85.6% (18,259)

95.9% (558)

99.3% (21,185)

100% (582)

39.6% (8449)

59.5% (346)

15.1% (3214)

18.6% (108)
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Abstract
Pasture heaves, also termed summer pasture-associated recurrent airway
obstruction (SPARAO), is an environmentally induced disease affecting horses
maintained on pasture during conditions of high heat and humidity and is characterized
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by seasonal exacerbation of asthma-like signs with neutrophilic airway inflammation. A
similar syndrome commonly termed ‘heaves’ or recurrent airway obstruction (RAO),
affects horses maintained indoors in temperate regions and is recognized as a
spontaneous asthma model. During exacerbation, signs vary from mild to life-threatening
episodes of wheezing, coughing, and chronic debilitating labored breathing. Among
spontaneous animal models of asthma, both stall (RAO) and pasture-associated forms of
‘heaves’ have the distinction of airway inflammation that is predominantly neutrophilic a characteristic that is now increasingly recognized in more severe and chronic forms of
asthma. Building upon our prior evidence that protein functions in normal lung fluids are
conserved across horse, human, and mouse, this investigation identifies proteins in lung
fluid from horses with pasture heaves that contribute to neutrophilic airway inflammation
and identifies conservation of these protein signatures in asthma.
Shotgun proteomic analysis using 1D liquid chromatography nanospray ionization
tandem mass spectrometry was employed to identify proteins in the cell-free
bronchoalveolar lavage fluid (BALF) from 6 pasture heaves-affected and 6 nonaffected
herdmates during seasonal clinical exacerbation. Peptides were identified and quantified
using the SEQUEST and PROTQUANT algorithms, respectively. 1003 proteins were
identified (P<0.05; 472 unique to nonaffected, 417 unique to affected, and 114 proteins
common to both groups). The contributions of each protein to 13 neutrophil functions
described in the Ingenuity Knowledge Base ® were modeled as the product of magnitude
of expression multiplied by its effect (i.e. -1, 0, +1). When compared to proteins in the
BALF of control horses, proteins in BALF from diseased favor airway neutrophilic
inflammation by increasing migration, chemotaxis, adhesion, detachment, transmigration,
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and degranulation, while reducing activation, cell spreading, infiltration, phagocytosis,
respiratory burst, apoptosis, and clearance. This approach demonstrates the utility of
systems modeling to organize functional genomic datasets in order to characterize
complex molecular events associated with clinically relevant equine disease.
Key words: heaves, Equus caballus, horse, proteomics, neutrophil functional genomics
Platforms such as microarrays; next-generation
Introduction
Human asthma has been traditionally regarded as an allergic airway disease
mediated by Th2 cells and characterized by eosinophilic inflammation [1, 2]. However, it
is now well recognized that airway eosinophilia is present in as few as 50% of asthmatic
subjects [3] and that a sizeable subgroup of asthmatic patients have neutrophilic airway
inflammation. Though neutrophilic asthma and eosinophilic asthma are not mutually
exclusive, an association has been established between airway neutrophilic inflammation
and increased severity of signs in severe asthma [4-6], corticosteroid resistant asthma [79], asthma exacerbations [10], nocturnal asthma [11], ‘‘asthma in smokers’’ [12],
occupational asthma [13], and ‘‘sudden onset’’ fatal asthma [14].
Two naturally occurring environmentally induced asthma-like syndromes affect
out bred populations of animals: equine heaves and feline asthma [15]. Two forms of
equine heaves are recognized: a stable-associated form exacerbated by mold and dust
when horses are maintained in stalls [16], and a summer pasture-associated form
affecting grazing horses [17]. Airway inflammation in both barn-associated, and in
pasture heaves (aka Recurrent Airway Obstruction, SPARAO), may be devoid of
eosinophils, and is consistently and predominantly neutrophilic. [16, 18-21]. Other
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features shared with human asthma include genetic linkages [19], reversible
bronchoconstriction triggered by environmental aeroallergen challenge, airway
remodeling, bronchial hyperresponsiveness, chronic airway inflammation and
responsiveness to β2-adrenoceptor agonists and corticosteroids. These clinical parallels
have lead to the recognition of heaves as a unique spontaneous model of neutrophilic
asthma [16, 18-21].
Neutrophilic inflammation has been shown to correlate to poor outcome in other
chronic lung diseases in addition to asthma, including bronchiolitis obliterans in lung
transplant recipients [22], and COPD [23] where the correlation is independent of viral or
bacterial infection. Neutrophil elastase also correlates to declining lung function in cystic
fibrosis [24]. Neutrophilic inflammation has been linked to worsening prognosis in other
organs, for example, with intracranial hemorrhage [25], alcoholic hepatitis [26],
myocardial infarction [27-31], pulmonary embolism [32], peripheral vascular disease
following angioplasty, tumor recurrence in hepatocellular carcinoma [33, 34], colorectal
tumors [35], and lung cancer [36]. Accordingly, identifying proteins that contribute to
neutrophilic airway inflammation in horses with pasture heaves contributes to the
identification of molecular signatures that herald advancing disease, and identifies targets
for investigating directed therapies to moderate neutrophilic inflammation.
The concept has been advanced that a state of homeostasis within a network of
eukaryotic proteins (proteostasis) “enables healthy cell and organismal development and
aging, and protects against disease [37].” Disease then reflects challenges to the integrity
of this network of interacting proteins (proteome) that direct the generation, maintenance,
and removal of proteins to achieve normal function. An emergent area of research is the
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relationship between airways stress diseases (ASDs), including chronic obstructive
pulmonary disease (COPD), emphysema and asthma, and disorders of proteostasis [38].
Congruent with the concept of disordered proteostasis, we hypothesize that changes in
the protein composition of fluid in the airways of horses with pasture heaves alter
functional attributes of neutrophils in ways that contribute to airway neutrophil
accumulation that characterizes pasture heaves.
Identifying how changes in the BALF proteome associated with disease
contribute to increased airway neutrophilic inflammation enables recognition of shared
regulatory events in asthma and pasture heaves, and also presents the ability to inform
understanding of the similar roles of neutrophils in human asthma and pasture heaves.
Here we employ systems modeling of the BAL proteome of horses experiencing
exacerbation of summer heaves, and that of asymptomatic controls exposed to identical
aeroallergen challenge, to evaluate differences in the regulation of thirteen neutrophil
functions: migration, activation, chemotaxis, adhesion, cell spreading, detachment,
transmigration, infiltration, phagocytosis, respiratory burst, degranulation, apoptosis, and
clearance.
Methods
Cell free bronchoalveolar lavage fluid (BALF) samples:
BALF was collected from six horses with pasture heaves during clinical disease
exacerbation, and six clinically normal control horses by manual aspiration as has been
previously described [39, 40]. Samples were placed immediately on ice, transported to
the laboratory, centrifuged (N x g for 10 minutes) to derive cell free BALF, and aliquots
of supernate were frozen at -80°C for subsequent proteomic analysis.
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Protein isolation, tryptic digestion, and LC MS/MS
Composite samples containing 100 ug of cell free BALF protein from the 6
control and 6 pasture heaves affected horses were created. Aliquots containing 75 ug of
protein were subjected to proteomic analysis using one dimensional liquid
chromatography (1D LC) nanospray ionization in triplicate as described [41] except that
we did not perform differential detergent fractionation. Precursor mass scans were
performed using repetitive MS scans immediately followed by three MS/MS scans of the
three most intense MS peaks.
Protein identification
Searches were performed using TurboSEQUESTTM (Bioworks Browser 3.3;
ThermoElectron). Mass spectra and tandem mass spectra were searched against an in
silico trypsin-digested database of equine nonredundant RefSeq proteins downloaded
from the National Center for Biotechnology Institute.
SEQUEST search results were filtered using a decoy search based probabilistic
method, in which only peptides with a probability <0.05 were considered to be correct.
Proteins with peptides passing the filter criteria were evaluated for differential expression
using an Xcorr resampling technique. Probability of differential expression was
calculated for each protein and those proteins with a p-value < 0.05 were considered
differentially expressed [42].
GO-based quantitative modeling: effects of BALF proteins on neutrophil function
Systems modeling was performed to test the hypothesis that proteins in the
airways of horses with pasture heaves have the potential to modify neutrophil functions
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in a manner that contributes to neutrophilic airway inflammation. Gene ontology (GO) is
the de facto method for assigning molecular function to proteins [43]. Accordingly,
proteins identified in BALF from affected and control horses were characterized for their
contributions to eleven Gene Ontology terms that describe neutrophil functions:
migration, activation, chemotaxis, adhesion, cell spreading, detachment, transmigration,
infiltration, phagocytosis, respiratory burst, and apoptosis. The effects of BALF proteins
on degranulation and neutrophil clearance, functions of neutrophils in the Ingenuity
Knowledge Base, but not in the Gene Ontology, were also evaluated. Proteins were
individually biocurated according to the principles of the GO consortium [44] using
manual literature searches in PubMed and with Ingenuity Pathway’s Analysis® (IPA)
software to identify their effects on the 13 neutrophil functions. Because IPA does not
accept equine gene products for upload and analysis, the human, mouse, and rat orthologs
were identified for each equine protein using Ensembl BioMart (Version 0.7, Ensembl 59
set) [45] and uploaded to IPA. Peer reviewed manuscripts identified from both the IPA
and PubMed were read and the effect of the protein on each of the thirteen neutrophil
functions was scored as pro (+1), anti (-1), no effect (0), or no data. The potential of each
protein to modify each of the thirteen neutrophil functions was approximated as the
product of magnitude of expression multiplied by its effect (i.e. -1, 0, +1) and the net
effect of BALF proteins within each functional category was tabulated; similar to the
method used for modeling effects on GO terms via GOModeler [46]. These net effects
are represented graphically for pasture heaves and control horses in Figure 5.1.
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Results
Neutrophil relevant BAL proteome
1003 total proteins were identified in BALF from diseased and control horses:
417 proteins were unique to diseased BALF, 472 proteins were unique to control BALF,
and 114 proteins were identified in BALF from diseased and control horses. 108 proteins
in BALF had sufficient criteria to allow statistical determination of significance to
differential expression between diseased and control groups. 64 of these 108 proteins
were differentially expressed between diseased and control groups (Supplemental File 4
and 5), and 44 had no difference in expression (Supplemental File 6). Of the 64 proteins
with significant differences in differential expression between groups, 12 proteins were
unique to diseased BALF, 27 proteins were unique to control BALF, and 26 were
identified in both diseased and control BALF. 5 of these 26 proteins were significantly
over-expressed in diseased BALF. The remaining 21 proteins had significantly greater
expression in control BALF. Accordingly, 17 proteins had significantly greater
expression in diseased BALF (Supplemental File 4) and 48 proteins had significantly
greater expression in control BALF (Supplemental File 5).
Evidence of biological activity in one or more of the thirteen neutrophil functions
was identified for 106 of the 1003 identified proteins. BALF proteins from horses with
pasture heaves and control horses are summarized according to their ability to impact
neutrophil functions in (Supplemental File 7). 34 of these 106 proteins were unique to
diseased BALF, 48 were unique to control BALF and 24 were identified in both diseased
and control BALF. 27 of the 106 proteins known to modify neutrophil function were
significantly differentially expressed between control and diseased BALF. 4 were unique
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to diseased BALF, 11 were unique to control BALF, and 12 proteins identified in both
diseased and control BALF had significantly greater expression in control BALF.
Accordingly, 4 proteins modifying neutrophil function had significantly greater
expression in diseased BALF and 23 proteins had significantly greater expression in
control BALF (Supplemental 7).
Bioinformatic modeling: effects of BALF proteins on neutrophil function
Expression modeling of diseased and control BALF proteomes (Figure 5.1)
demonstrates a net increase in proteins that induce neutrophil migration, chemotaxis,
adhesion, detachment, transmigration, and degranulation in the BALF of diseased relative
to control horses. This reflects a net negative regulation of migration, chemotaxis,
adhesion, detachment, transmigration, and degranulation by proteins in control BALF,
with proteins in diseased BALF facilitating a partial release of the net negative regulation
of these neutrophil functions. The release of negative regulation by the diseased BALF
proteome was negligible for neutrophil detachment and degranulation relative to other
neutrophil functions. By contrast, a net decrease in proteins responsible for neutrophil
activation, cell spreading, phagocytosis, apoptosis, and clearance was identified in the
BALF of diseased relative to control horses. This reflects a net positive regulation of
activation, cell spreading, phagocytosis, apoptosis, and clearance by proteins in control
BALF, with proteins in diseased BALF facilitating partial decrease in the net positive
modulation that characterizes homostasis. Respiratory burst is a specific facet of
neutrophil activation that was neutralized by proteins in the BALF proteome of both
controls and diseased horses. Neutrophil infiltration was positively regulated by proteins
in control BALF, an effect reversed by the diseased BALF proteome.
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Discussion
Though at least 50% of human asthmatics demonstrate neutrophilic inflammation
in BALF, which correlates to increased clinical severity and resistance to corticosteroid
therapy [3, 47, 48], regulatory mechanisms responsible for neutrophilic asthma are poorly
characterized. Complicating this effort is the difficulty in attaining purified populations of
airway neutrophils, resulting in a predominance of investigations that employ peripheral
blood neutrophils, for which there is growing evidence that these cells do not behave in
manners that mirror their airway counterparts [49, 50]. Deciphering regulatory
mechanisms associated with airway neutrophilia and the major protein effectors
responsible for these changes has the potential to identify molecular events that herald
advancing airway disease, as well as avenues for pharmacologic intervention. Systems
modeling provides a unique opportunity to translate a large amount of data from high
throughput technologies including microarrays, proteomics, and transcriptomics, into a
better understanding of complex biological phenomena.
In this work, systems modeling of the BALF proteome from horses with summer
heaves was used to provide insight into the molecular events that contribute to
neutrophilic airway inflammation, a characteristic of both heaves and asthma that is not
addressed by rodent models. Relative to the control BALF proteome, proteins in BALF
from summer heaves-affected horses increase neutrophil migration, chemotaxis,
adhesion, and transmigration, and to a lesser extent, also increase detachment and
degranulation. An increase in neutrophil migration, chemotaxis, transmigration, and
detachment clearly favor the movement of neutrophils into the airways, congruent with
airway neutrophilic inflammation that is characteristic of pasture heaves. Increased
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neutrophil migration [51], chemotaxis [52, 53], adhesion [54], and degranulation have
previously been reported in asthma, with degranulation increases corresponding to
disease severity [55]. Our findings are also consistent with increased neutrophil migration
[56] and chemotaxis [57] reported in barn associated heaves. Despite expanding
knowledge of how individual proteins modify neutrophil movement in asthma, changes
in neutrophil detachment and transmigration that occur during neutrophilic forms of
asthma are not documented. Rather, increased airway neutrophils are considered a priori
evidence of increased neutrophil detachment and transmigration [14, 58, 59]. Increased
transmigration of neutrophils into the airway is a feature of several inflammatory
diseases, including bronchitis and chronic obstructive pulmonary disease [58].
Proteins in the BALF proteome of diseased horses decreased neutrophil
activation, spreading, infiltration, phagocytosis, apoptosis, and clearance. Similar
decreases in neutrophil phagocytosis, clearance, and apoptosis are identified in asthmatic
patients [60-63], and decreased apoptosis of airway neutrophils [64, 65] has been
identified in horses with the barn-associated form of heaves. Decreased apoptosis
contributes to airway neutrophilic inflammation that characterizes asthma and RAO by
increasing neutrophil persistence in the airway. Similarly, neutrophil activation and
phagocytosis program neutrophils for death [66-68], such that decreasing these activities
contributes to neutrophil persistence and airway neutrophilic inflammation. We also
identified an overall decrease in proteins that favor neutrophil clearance from the
airways, again consistent as a contributing factor to airway neutrophilic inflammation
[69].
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While proteins in BALF of diseased horses decreased neutrophil activation,
isolated measures of neutrophil activation are reported to increase in asthma [70-74].
However, neutrophil activation is a complex and multifaceted neutrophil function.
Respiratory burst is a specific component of neutrophil activation. In this investigation,
BALF proteins that increase and those that decrease respiratory burst yielded a net null
effect on this neutrophil function in both control and diseased horses. Literature
demonstrates that respiratory burst of blood derived neutrophils from asthmatics exceeds
nonasthmatics [49, 75, 76]. However, Marcal et al. (2004) clarified that significant
differences in measures of respiratory burst are influenced by disease severity and are not
immediately evident in ex vivo neutrophils, occurring only in more severe asthmatics
following ex vivo incubations periods of 25 minutes [49]. Further, the respiratory burst of
airway neutrophils, which is congruent with our model, has been poorly characterized.
Lacy et al. (2003) identified decreased respiratory burst activity in neutrophils from
induced sputum of asthmatics, relative to controls [50]. However, this finding must be
considered with the knowledge that beta agonist and corticosteroid therapy were not
withheld from the asthmatic group. Despite evidence that selected measures of neutrophil
activation are increased in asthma [70-74], our modeling indicates that the proteome
favors decreased neutrophil activation which would be fully consistent with neutrophil
persistence in the airways and the airway neutrophilic inflammation that characterizes
pasture heaves.
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Effect of BALF proteins on neutrophil function.

Effects of proteins from pasture heaves-affected and control horses on neutrophil functions are scored as pro (+1), anti (-1), no effect (0), or no data. The potential of each
protein to modify each of the neutrophil functions was approximated as the product of magnitude of expression multiplied by its effect (i.e. -1, 0, +1) and the net regulatory
effect of BALF proteins within each functional category was tabulated.

Figure 5.1
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APPENDIX A
SUPPLEMENTAL FILE INFORMATION
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The following supplemental files were created using Microsoft Office Excel 2007
and saved as PDF files. One exception is Supplemental File 2, which was created using
Microsoft Office Word 2007. The PDF files were compressed into a .rar file using
WinRAR. They can be accessed on the Mississippi State University Electronic Thesis
and Dissertation Database, available at http://sun.library.msstate.edu/ETD-db/. Once
downloaded, the files can be extracted using an unzipping program such as WinRAR or
WinZip. Files can be viewed using Adobe Reader software or other software for viewing
PDF files.
Supplemental File 1: Example of ArrayIDer Output
To facilitate linking array data to information in multiple public databases,
ArrayIDer retrieves structural annotations for array elements and provides corresponding
identifiers used in public databases (including UniProtKB, Ensembl, RefSeq, IPI and
UniGene). The identifiers are: probe name, horse gene ID, the public accession number,
the Unigene ID, any gene symbols it has, the Entrez Gene ID, its RefSeq accession
number, and its UniProtKB ID. This is only an example, and the rest of the equine array
data from ArrayIDer will be made publicly available via AgBase.
Supplemental File 2: Detailed methods for Chapter IV
Detailed methods for Chapter IV: Functional Modelling of an Equine
Bronchoalveolar Lavage Fluid Proteome Provides Experimental Confirmation and
Functional Annotation of Equine Genome Sequences.
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Supplemental File 3: List of Proteins Identified in Control Equine BALF
A list of all 582 unique proteins from the cell-free BALF of normal horses, and
lists the 88 proteins that did not have orthologous proteins and were therefore not
submitted for Ingenuity Pathways Analysis.
Supplemental File 4: List of Proteins with Significantly Increased Expression in
Pasture Heaves BALF
A list of the 17 proteins with significantly greater expression in diseased BALF.
RefSeq ID, gene symbol, protein description, peptide counts, and corrected P values are
listed for each.
Supplemental File 5: List of Proteins with Significantly Increased Expression in
Control BALF
A list of the 48 proteins with significantly greater expression in control BALF.
RefSeq ID, gene symbol, protein description, peptide counts, and corrected P values are
listed for each.
Supplemental File 6: List of Proteins with No Difference in Expression Between
Pasture Heaves and Control BALF
A list of the 44 statistically relevant proteins with expression values but with no
difference in expression between pasture heaves and control horse BALF. RefSeq ID,
gene symbol, protein description, peptide counts, and corrected P values are listed for
each.
Supplemental File 7: Proteins Influencing Neutrophil Function
106 BALF proteins from horses with pasture heaves and control horses are
summarized according to their ability to impact neutrophil functions. 4 proteins
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modifying neutrophil function had significantly greater expression in diseased BALF and
23 proteins had significantly greater expression in control BALF. The remaining 79
proteins had no significant difference in expression between disease and control BALF.
RefSeq ID, gene symbol, protein description, peptide counts, and corrected P values are
listed for each, as well as their involvement in the thirteen neutrophil categories.
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